

Clinical Guidelines for Stroke Management

**Chapter 2 of 8:
Early assessment and diagnosis**

This is the second in a series of eight Clinical Guideline chapters that provide evidence-based recommendations for recovery from stroke and TIA in adults.

Contact

Stroke Foundation
Melbourne, Victoria, Australia
guidelines@strokefoundation.org.au
+61396701000
<https://informme.org.au/Guidelines>

Sponsors/Funding

The Stroke Foundation gratefully acknowledges the previous financial assistance provided by the Australian Government, Medical Research Future Fund. The development of the recommendations has not been influenced by the views or interests of the funding body.

Disclaimer

These Clinical Guidelines are a general guide to appropriate practice, to be followed subject to the clinician's judgment and the patient's preference in each individual case. The Clinical Guideline is designed to provide information to assist decision-making and are based on the best evidence available at the time of development. The Clinical Guidelines can be viewed at www.informme.org.au - Citation: Stroke Foundation. Clinical Guidelines for Stroke Management. Melbourne Australia. © No part of this publication can be reproduced by any process without permission from the Stroke Foundation. June 2022.

Sections

Summary of recommendations..... 4

Introduction 8

Methodology 11

Clinical questions..... 14

Early assessment and diagnosis - overview 15

Transient ischaemic attack..... 16

Assessment of suspected stroke 26

Investigations..... 32

 Imaging..... 32

 Cardiac investigations..... 44

Glossary and abbreviations 52

References..... 58

Summary of recommendations

Introduction

Methodology

Clinical questions

Early assessment and diagnosis - overview

Transient ischaemic attack



Strong recommendation

- All patients with suspected transient ischaemic attack (TIA), i.e. focal neurological symptoms due to focal ischaemia that have fully resolved, should have urgent clinical assessment. (Lavalley et al. 2007 [25]; Rothwell et al. 2007 [26]) *(Refer to the 'Practical Information' section for further useful information)*
- Patients with symptoms that are present or fluctuating at time of initial assessment should be treated as having a stroke and be immediately referred for emergency department and stroke specialist assessment, investigation and reperfusion therapy where appropriate. (Lavalley et al. 2007 [25]; Rothwell et al. 2007 [26])
- In pre-hospital settings, high risk indicators (e.g. crescendo TIA, current or suspected AF, current use of anticoagulants, carotid stenosis or high ABCD² score) can be used to identify patients for urgent specialist assessment. (Lavalley et al. 2007 [25]; Rothwell et al. 2007 [26])



Strong recommendation

When TIA patients present to primary care, the use of TIA electronic decision support, when available, is recommended to improve diagnostic and triage decisions. (Ranta et al. 2015 [15])



Weak recommendation against

Updated evidence, no change in recommendation

In TIA patients, use of the ABCD² risk score in isolation to determine the urgency of investigation may delay recognition of atrial fibrillation and symptomatic carotid stenosis in some patients and should be avoided. (Wardlaw et al. 2015 [8])



Strong recommendation

All TIA patients with anterior circulation symptoms should undergo early carotid imaging with CT angiography (aortic arch to cerebral vertex), carotid Doppler ultrasound or MR angiography. Carotid imaging should preferably be done during the initial assessment but should not be delayed more than 2 days (see [Imaging](#)).



Weak recommendation

Patients with TIA should routinely undergo brain imaging to exclude stroke mimics and intracranial haemorrhage. MRI, when available, is recommended to improve diagnostic accuracy (see [Imaging](#)).



Strong recommendation

Patients with suspected TIA should commence secondary prevention therapy urgently (see [Secondary Prevention](#)).



Strong recommendation

- All patients with TIA should be investigated for atrial fibrillation with ECG during initial assessment and referred for possible prolonged cardiac monitoring as required (see [Cardiac Investigations](#)).
- TIA patients with atrial fibrillation should commence anticoagulation therapy early after brain imaging has excluded haemorrhage, unless contraindicated (see [Anticoagulant therapy](#) in [Secondary Prevention](#)).

Good practice statement

Consensus-based recommendations

- All patients and their family/carers should receive information about TIA, screening for diabetes, tailored advice on lifestyle modification strategies (smoking cessation, exercise, diabetes optimisation if relevant – see [Secondary prevention](#)), return to driving (see [Driving in Community participation and long-term care](#)) and the recognition of signs of stroke and when to seek emergency care.
- All health services should develop and use a local TIA pathway covering primary care, emergency and stroke specialist teams to ensure patients with suspected TIA are managed as rapidly and comprehensively as possible within locally available resources.

Assessment of suspected stroke

Strong recommendation

All suspected stroke patients who have been pre-notified to the stroke or ED team, and who may be candidates for reperfusion therapy, should be met at arrival and assessed by the stroke team or other experienced personnel. (Meretoja et al. 2012 [40]; Meretoja et al. 2013 [39])

Weak recommendation

Updated evidence, no change in recommendation

The use of clinical screening tools to identify stroke by ED staff is recommended where an expert stroke team is unable to immediately assess a patient. (Zhelev et al. 2019[105])

Info Box

Practice points

- Initial diagnosis should be reviewed by a clinician experienced in the evaluation of stroke.
- Stroke severity should be assessed and recorded on admission by a trained clinician using a validated tool (e.g. NIHSS).
- A blood glucose reading should be taken to improve specificity (hypoglycaemia can present as a 'stroke mimic').

Investigations

Imaging

Strong recommendation

Brain imaging

All patients with suspected stroke who are candidates for reperfusion therapies should undergo brain imaging immediately. All other suspected stroke patients should have an urgent brain CT or MRI ('urgent' being immediately where facilities are available and preferably within 60 minutes). (Brazzelli et al. 2009 [41])

Weak recommendation

In patients with suspected stroke and TIA, MRI is more sensitive and specific than non-contrast CT and is the preferred modality when diagnostic confirmation is required. (Brazzelli et al. 2009 [41])

Good practice statement

Consensus-based recommendation

Either CT or MRI are acceptable acute imaging options but these need to be immediately accessible to avoid delaying reperfusion therapies.

Strong recommendation

If using CT to identify hyperdense thrombus, thin slice (< 2 mm) non-contrast CT should be used rather than the standard 5 mm slices to improve diagnostic sensitivity for vessel occlusion. (Mair et al. 2015 [46])

Weak recommendation

CT perfusion imaging may be used in addition to routine imaging to improve diagnostic and prognostic accuracy. (Biesbroek et al. 2012 [49])

Info Box Updated

Practice points

- If a patient with stroke develops neurological deterioration, immediate clinical assessment and further brain imaging (CT or MRI) should be considered.
- Routine brain imaging approximately 24 hours after reperfusion therapies have been administered is recommended to identify haemorrhagic transformation and delineate the extent of infarction, both of which are important when making decisions about antithrombotic therapy and DVT prophylaxis.

Strong recommendation

Vascular imaging

- All patients who would potentially be candidates for endovascular thrombectomy should have vascular imaging from aortic arch to cerebral vertex (CTA or MRA) to establish the presence of vascular occlusion as a target for thrombectomy and to assess proximal vascular access. (Goyal et al. 2016 [52]; Broderick et al. 2013 [58])
- All other patients with carotid territory symptoms who would potentially be candidates for carotid re-vascularisation should have early vascular imaging to identify stenosis in the ipsilateral carotid artery. CT angiography (if not already performed as part of assessment for reperfusion therapies), Doppler ultrasound or contrast-enhanced MR angiography are all reasonable options depending on local experience and availability. (Netuka et al. 2016 [42]; Chappell et al. 2009 [43]; Nonent et al. 2011 [44]; Anzidei et al. 2012 [69])

Info Box

Practice points

- In ischaemic stroke and TIA patients, routinely imaging the entire vasculature from aortic arch to cerebral vertex with CTA or MRA is encouraged to improve diagnosis, recognition of stroke aetiology and assessment of prognosis.
- The administration of intravenous iodinated contrast for CT angiography/perfusion, when clinically indicated, should not be delayed by concerns regarding renal function. Post-hydration with intravenous 0.9% saline is advisable. (RANZCR guidelines 2016 [64]; Ang et al. 2015 [63]).

Info Box

Practice point

Vascular imaging should not be performed for syncope or other non-focal neurological presentations.

Cardiac investigations

Weak recommendation

Initial ECG monitoring should be undertaken for all patients with stroke. The duration and mode of monitoring should be guided by individual patient factors but would generally be recommended for at least the first 24 hours. (Kurka et al. 2015 [66])

Strong recommendation

For patients with embolic stroke of uncertain source, longer term ECG monitoring (external or implantable) should be used. (Afzal et al. 2015 [67])



Weak recommendation

Further cardiac investigations should be performed where clarification of stroke aetiology is required after initial investigations. In patients with ischaemic stroke, echocardiography should be considered based on individual patient factors. Transoesophageal echocardiography is more sensitive for suspected valvular, left atrial and aortic arch pathology. (Holmes et al. 2014 [68])

Glossary and abbreviations

Introduction

The Stroke Foundation is a national charity that partners with the community to prevent, treat and beat stroke. We stand alongside stroke survivors and their families, healthcare professionals and researchers. We build community awareness and foster new thinking and innovative treatments. We support survivors on their journey to live the best possible life after stroke.

We are the voice of stroke in Australia and we work to:

- Raise awareness of the risk factors, signs of stroke and promote healthy lifestyles.
- Improve treatment for stroke to save lives and reduce disability.
- Improve life after stroke for survivors.
- Encourage and facilitate stroke research.
- Advocate for initiatives to prevent, treat and beat stroke.
- Raise funds from the community, corporate sector and government to continue our mission.

The Stroke Foundation has been developing stroke guidelines since 2002 and in 2017 released the fourth edition. In order for the Australian Government to ensure up-to-date, best-practice clinical advice is provided and maintained to healthcare professionals, the NHMRC requires clinical guidelines be kept current and relevant by reviewing and updating them at least every five years. As a result, the Stroke Foundation, in partnership with Cochrane Australia, have moved to a model of living guidelines, in which recommendations are continually reviewed and updated in response to new evidence. This approach was piloted in a three year project (July 2018 -June 2021) funded by the Australian Government via the Medical Research Future Fund.

This online version of the *Clinical Guidelines for Stroke Management* updates and supersedes the Clinical Guidelines for Stroke Management 2017. The Clinical Guidelines have been updated in accordance with the 2011 NHMRC *Standard for clinical practice guidelines* and therefore recommendations are based on the best evidence available. The Clinical Guidelines cover the whole continuum of stroke care, across 8 chapters.

Review of the Clinical Guidelines used an internationally recognised guideline development approach, known as GRADE (Grading of Recommendations Assessment, Development and Evaluation), and an innovative guideline development and publishing platform, known as MAGICapp (Making Grade the Irresistible Choice). GRADE ensures a systematic process is used to develop recommendations that are based on the balance of benefits and harms, patient values, and resource considerations. MAGICapp enables transparent display of this process and access to additional practical information useful for guideline recommendation implementation.

Purpose

The *Clinical Guidelines for Stroke Management* provides a series of best-practice recommendations to assist decision-making in the management of stroke and transient ischaemic attack (TIA) in adults, using the best available evidence. The Clinical Guidelines should not be seen as an inflexible recipe for stroke management; rather, they provide a guide to appropriate practice to be followed subject to clinical judgment and patient preferences.

Scope

The Clinical Guidelines cover the most critical topics for effective management of stroke, relevant to the Australian context, and include aspects of stroke management across the continuum of care including pre-hospital, assessment and diagnosis, acute medical and surgical management, secondary prevention, rehabilitation, discharge planning, community participation, and management of TIA. Some issues are dealt with in more detail, particularly where current management is at variance with best practice, or where the evidence needs translation into practice.

The Clinical Guidelines do not cover:

- Subarachnoid haemorrhage;
- Stroke in infants, children and youth, i.e. <18 years old (refer to Australian Childhood Stroke Advisory Committee, *Guideline for the diagnosis and acute management of childhood stroke* – 2017, and Victorian Subacute Childhood Stroke Advisory Committee, *Guideline for the subacute management of childhood stroke* – 2019, <https://informme.org.au/Guidelines/Childhood-stroke-guidelines>); or
- Primary prevention of stroke. (Refer to *Guidelines for the management of absolute cardiovascular disease risk* 2012 (National Vascular Disease Prevention Alliance [5]) - <https://informme.org.au/en/Guidelines/Guidelines-for-the-assessment-and-management-of-absolute-CVD-risk>, and *Guideline for the diagnosis and management of hypertension in adults* 2016 (Heart Foundation [6]) - <https://www.heartfoundation.org.au/for-professionals/clinical-information/hypertension>).

Target audience

The Clinical Guidelines are intended for use by healthcare professionals, administrators, funders and policy makers who plan, organise and deliver care for people with stroke or TIA during all phases of recovery.

Development

The Guidelines are published in eight separate chapters:

[Pre-hospital care](#)

[Early assessment and diagnosis](#)

[Acute medical and surgical management](#)

[Secondary prevention](#)

[Rehabilitation](#)

[Managing complications](#)

[Discharge planning and transfer of care](#)

[Community participation and long-term care](#)

The Clinical Guidelines have been developed according to processes prescribed by the National Health and Medical Research Council (NHMRC) under the direction of an interdisciplinary working group. Refer to the document on [InformMe](#) that details the Interdisciplinary Working Group Membership and Terms of Reference.

Use

The primary goal of the Clinical Guidelines is to help healthcare professionals improve the quality of the stroke care they provide.

Guidelines differ from clinical or care pathways (also referred to as critical pathways, care paths, integrated care pathways, case management plans, clinical care pathways or care maps). Guidelines are an overview of the current best evidence translated into clinically relevant statements. Care pathways are based on best practice guidelines but provide a local link between the guidelines and their use.

In considering implementation of the Guidelines at a local level, healthcare professionals are encouraged to identify the barriers, enablers and facilitators to evidence-based practice within their own environment and determine the best strategy for local needs. Where change is required, initial and ongoing education is essential and is relevant to all recommendations in the Guidelines.

Aboriginal and Torres Strait Islander People

Refer to the document on [InformMe](#) for information regarding Aboriginal and Torres Strait Islander people.

Decision-making

Stroke survivors should be treated in accordance with the principles of shared decision-making contained within the *Acute Stroke Care Clinical Standard*, *Acute Stroke Services Framework 2019* and *Rehabilitation Stroke Services Framework 2013*, which include, among other things, that treatment should be patient-centred. Therefore, stroke survivors should be involved in decisions about their care at all times; but where they do not have capacity, or have limited capacity, family members should be involved in the decision-making.

Consent

The principles of informed consent underpin these Clinical Guidelines and therefore the wording of the recommendations are directed at the healthcare professional; that is, the intervention should/may be used, rather than offered, for the stroke patient. For patients with aphasia and/or cognitive disorders requiring formal consent, easy English or aphasia-friendly written versions of an information sheet and consent form should be offered and clearly explained to patients and their families in order to assist understanding and agreement.

Endorsement

The Clinical Guidelines have been endorsed (based on the 2017 version) by a number of organisations and associations. Refer to the document on [InformMe](#) that details the organisations formally endorsing the Clinical Guidelines.

Evidence gaps

Refer to the document on [InformMe](#) that details the gaps in evidence identified, noting areas for further research.

Reports

Refer to documents on [InformMe](#) - Technical Report, Administrative Report and Dissemination and Implementation Report.

Resources

Refer to documents on [InformMe](#) that provide supporting resources to assist with implementation of the Clinical Guidelines.

Publication Approval



Australian Government

National Health and Medical Research Council

The 2017 guideline recommendations were approved by the Chief Executive Officer of the National Health and Medical Research Council (NHMRC) on 25 July 2017 under Section 14A of the National Health and Medical Research Council Act 1992 with a subsequent amendment approved on 22 November 2017. Since moving to a continual (living) guideline model, further updates have been approved:

- 9 July 2018 (updated recommendations for neurointervention)
- 7 November 2019 (updated recommendations for thrombolysis, acute antiplatelet therapy, and patent foramen ovale management)
- 11 February 2021 (updated recommendations for oxygen therapy, cholesterol lowering targets, new acute antiplatelet agent, shoulder pain and weakness)
- 7 July 2021 (updated recommendations for standing, antiplatelet therapy, and activities of living)
- 22 December 2021 (updated recommendations for pre-hospital care, acute telehealth, head position, telehealth for rehabilitation, swelling of extremities, memory, management of atrial fibrillation, lifestyle modifications, and virtual reality for arm function)
- 5 August 2022 (updated recommendations for pre-hospital care [mobile stroke unit], assessment for rehabilitation, aphasia, dysarthria, prevention and treatment for depression, treatment of anxiety, personality and behaviour, pressure injury)
- 6 December 2022 (updated recommendations for aphasia and incontinence).
- 27 July 2023 (updated recommendations for driving, neurointervention, oxygen therapy, and central post-stroke pain).

In approving the guidelines recommendations the NHMRC considers that they meet the NHMRC standard for clinical practice guidelines. This approval is valid for a period of five years.

NHMRC is satisfied that the guideline recommendations are systematically derived, based on identification and synthesis of the best available scientific evidence and are developed for health professionals practising in an Australian health care setting.

This publication reflects the views of the authors and not necessarily the views of the Australian Government.

Disclaimer

These Clinical Guidelines are a general guide to appropriate practice, to be followed subject to the clinician's judgment and the patient's preference in each individual case. The Clinical Guidelines are designed to provide information to assist decision-making and are based on the best evidence available at the time of development.

Funding

The Stroke Foundation gratefully acknowledges the financial assistance provided to establish the living guidelines between 2018-2021 by the Australian Government, Medical Research Future Fund. Funding is currently being provided by the Australian Living Evidence Consortium (<https://livingevidence.org.au>) to assist the continuation of the Stroke Living Guidelines. The development of the final recommendations are not influenced by the views or interests of any funding body.

Citation

Stroke Foundation. Clinical Guidelines for Stroke Management. Available at <https://informme.org.au/en/Guidelines/Clinical-Guidelines-for-Stroke-Management>. Accessed [insert date, month and year and if applicable specific sections or chapters].

© No part of this publication can be reproduced by any process without permission from the Stroke Foundation. 2023.

Methodology

Development of questions

Questions have been extensively developed and reviewed over the four iterations of the guidelines. In this 'living' phase the Content Steering Group reviews the PICO questions on an annual basis. The clinical questions are listed at the start of each chapter. Individual PICOs (population, intervention/s, comparator, outcomes) are listed in the research evidence section as related to each topic or recommendation.

Literature identification

On a monthly basis, we monitor the literature for relevant, new evidence by screening all randomised controlled trials or systematic reviews related to stroke published in the Pubmed database. One member of the project team initially screens all abstracts and excludes clearly irrelevant studies. Potentially included studies are allocated to relevant topics covered by the guidelines and a second member of the project team reviews and confirms included studies prior to sending to the relevant working group members. In addition, each month new economic studies and studies related to patient values and preferences are also captured.

Clinical expert review

Where new evidence has been identified by the project team a summary is sent to content experts who review and make a final decision to include or exclude the study and also to assess the potential impact of the new evidence on current recommendations. As a result of this assessment one of two options will be communicated for each topic:

- a. New evidence is unlikely to change current recommendations: review and potentially integrate information in the next review cycle; or
- b. New relevant evidence may change current recommendations: rapidly review.

Data extraction, updating evidence summary and GRADE profile

For rapid updates, the project team incorporates the new evidence into the existing body of evidence by:

- Updating the Summary of Findings table including the risk of bias assessment
- Review any additional studies related to Preferences and values of patients on the topic

Concurrently members of the economic working group review newly published economic studies.

The project team then drafts changes to the overall summary (GRADE profile). This profile is then reviewed and modified by clinical content experts and people with relevant lived experience (consumers). Finally changes to the changes to the recommendation, rationale and practical considerations are considered, discussed and agreed.

Draft changes are then circulated to the wider expert working groups (including consumer panel) for internal review. Once signed off by the Steering Group a period of public consultation is undertaken. Feedback is then reviewed and any changes made in response to feedback before finally submitting to the National Health and Medical Research Council (NHMRC) for approval.

Brief summary of GRADE

The Guidelines were developed following the GRADE methodology (Grading of Recommendations, Assessment, Development and Evaluation).

GRADE 'evidence to decision' framework includes a minimum of four factors to guide the development of a recommendation and determine the strength of that recommendation:

1. The balance between desirable and undesirable consequences.
2. Confidence in the estimates of effect (quality of evidence).
3. Confidence in values and preferences and their variability (clinical and consumer preferences).
4. Resource use (cost and implementation considerations).

For full details of how GRADE is used for developing clinical recommendations, refer to the GRADE handbook, available at: <http://gdt.guidelinedevelopment.org/app/handbook/handbook.html>.

Strength of recommendations

The GRADE process uses only two categories for the strength of recommendations, based on how confident the guideline panel is that the "desirable effects of an intervention outweigh undesirable effects [...] across the range of patients for whom the recommendation is intended" (GRADE Handbook):

- Strong recommendations: where guideline authors are certain that the evidence supports a clear balance towards either desirable or undesirable effects; or
- Weak recommendations: where the guideline panel is uncertain about the balance between desirable and undesirable effects.

These strong or weak recommendations can either be for or against an intervention. If the recommendation is against an intervention

this means it is recommended NOT to do that intervention. There are a number of recommendations where we have stated that the intervention may only be used in the context of research. We have done this because these are guidelines for clinical practice, and while the intervention cannot be recommended as standard practice at the current time, we recognise there is good rationale to continue further research.

The implications of a strong or weak recommendation for a particular treatment are summarised in the GRADE handbook as follows:
Table 1: Implications of GRADE recommendation categories (for a positive recommendation) for patients, clinicians and policy makers.
Source: GRADE Handbook (<http://gdt.guidelinedevelopment.org/app/handbook/handbook.html>)

	Strong Recommendation	Weak Recommendation
For patients	Most individuals in this situation would want the recommended course of action and only a small proportion would not.	The majority of individuals in this situation would want the suggested course of action, but many would not.
For clinicians	Most individuals should receive the recommended course of action. Adherence to this recommendation according to the guideline could be used as a quality criterion or performance indicator. Formal decision aids are not likely to be needed to help individuals make decisions consistent with their values and preferences.	Recognise that different choices will be appropriate for different patients, and that you must help each patient arrive at a management decision consistent with her or his values and preferences. Decision aids may well be useful helping individuals making decisions consistent with their values and preferences. Clinicians should expect to spend more time with patients when working towards a decision.
For policy makers	The recommendation can be adapted as policy in most situations including for the use as performance indicators.	Policy making will require substantial debates and involvement of many stakeholders. Policies are also more likely to vary between regions. Performance indicators would have to focus on the fact that adequate deliberation about the management options has taken place.

For topics where there is either a lack of evidence or insufficient quality of evidence on which to base a recommendation but the guideline panel believed advice should be made, statements were developed based on consensus and expert opinion (guided by any underlying or indirect evidence). These statements are labelled as 'Practice statements' and correspond to 'consensus-based recommendations' outlined in the NHMRC procedures and requirements.

For topics outside the search strategy (i.e. where no systematic literature search was conducted), additional considerations are provided. These are labelled 'Info Box' and correspond to 'practice points' outlined in the NHMRC procedures and requirements.

Explanation of absolute effect estimates used

The standardised evidence profile tables presented in the Clinical Guidelines include "Absolute effect estimates" for dichotomous outcomes. These represent the number of people per 1000 people expected to have the outcome in the control and intervention groups. This estimated risk in people receiving the intervention is based on a relative effect estimate which might be adjusted, e.g. to account for baseline differences between participants or when effect estimates have been pooled from different studies in a systematic review and adjusted to account for the variance of each individual estimate. Therefore, this estimated risk in the intervention group may differ from the raw estimate of the intervention group risk from the corresponding study. The estimated risk reflects the best estimate of the risk in the relevant population, relative to the risk observed among patients receiving the control or comparator intervention.

Wherever possible (i.e. when the relevant study reported enough information to allow the calculation to be done), these estimates were calculated using the following procedure:

1. Obtain the relative effect estimate (odds ratio or relative risk) and confidence interval from the best available study (systematic review or primary study) providing evidence about the effects of the intervention.
2. Use the observed number of events in the control group of the same study to calculate a baseline risk per 1000 people (or "assumed control risk").
3. Calculate an estimate of the corresponding risk per 1000 in people receiving the intervention using the relative effect estimate. This can be done using methods based on the formulas for calculating absolute risk reductions provided in the *Cochrane Handbook for Systematic*

Reviews of Interventions (<http://handbook.cochrane.org/>). Applying the same calculations to the upper and lower bounds of the confidence interval for the relative effect estimate gives a confidence interval for the risk in the intervention group, which is then used to calculate the confidence interval for the difference per 1000 people, reported in the evidence tables.

Cost effectiveness summaries

There are several important points to consider when interpreting the cost-effectiveness information provided in the *Resources and Other Considerations* sections of the Clinical Guidelines.

Firstly, an intervention can be cost-effective without being cost-saving. This means that although there is an additional cost for the health benefits gained from the intervention, the intervention is still considered worthwhile. The incremental cost-effectiveness ratios (ICER) presented (e.g. cost per quality adjusted life year gained) are an indication of the cost-effectiveness or “value-for-money”, with lower ICERs indicating better cost-effectiveness of an intervention.

Secondly, whether or not the intervention is cost-effective is a judgment call; and should reflect a society’s willingness-to-pay to have the intervention for the potential outcomes achieved. An ICER that is approximately or equivalent to US\$50,000 has been commonly used by researchers in the past as a threshold for judging an intervention as being cost-effective (<http://www.nejm.org/doi/full/10.1056/NEJMp1405158#t=article>). However, no scientific basis for this threshold exists and actual willingness-to-pay may differ. For example, in a survey of 1000 Australian respondents conducted in 2007, the willingness-to-pay for an additional quality adjusted life year in Australia was estimated to be \$64,000 (<https://www.ncbi.nlm.nih.gov/pubmed/19382128>).

Thirdly, there is no absolute threshold for determining whether an intervention should be funded based on the ICER (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153921/>). ICERs are only one of the major factors considered in priority setting (the process to decide which interventions should be funded within a given resource constraint). Other considerations include affordability, budget impact, fairness, feasibility and other factors that are important in the local context (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153921/>).

Lastly, in areas where there are no data from economic evaluations that support the recommendations or practice statements, it remains unclear whether the additional costs of providing the intervention above usual care for the additional potential benefits obtained is justified. However, this should not detract from implementing the Clinical Guideline recommendations.

Use of language related to timing of interventions

Immediate: without delay, or within minutes, not hours (life critical action required).

Urgent: minutes to several hours (immediate action but not life critical).

Very early: within hours and up to 24 hours.

Early: within 48 hours.

For all Clinical Guideline recommendations we make the assumption that healthcare professionals will be appropriately qualified and skilled to carry out the intervention.

Clinical questions

- 2.1 What clinical assessment tools and investigations improve diagnostic accuracy and outcomes for people with suspected TIA?
- 2.2 Do clinical assessment tools improve diagnostic accuracy in the emergency department?
- 2.3 What is the optimal modality for brain imaging for suspected acute stroke?
- 2.4 What is the optimal modality for cardiac investigations for possible atrial fibrillation?
- 2.5 What is the optimal modality for carotid/vascular imaging?

Early assessment and diagnosis - overview

The aim of assessment of a patient with suspected stroke or TIA is to:

- Confirm the diagnosis,
- Identify and treat the cause,
- Guide early rehabilitation, and
- Guide relevant early secondary prevention to prevent complications or stroke recurrence.

Appropriate diagnosis and immediate referral to a stroke team is particularly important given advances in reperfusion therapies. Strong working relationships are required between emergency department staff and the stroke team to improve timely assessment and early management.

This chapter will discuss transient ischaemic attack, rapid assessment in the emergency department, and investigations (brain and vascular imaging and cardiac investigations).

Transient ischaemic attack

Transient ischaemic attack (TIA) is defined here as focal neurological symptoms due to focal ischaemia that have fully resolved. TIA is a medical emergency. The highest risk of stroke occurring following TIA is within the first 2 days. TIA requires rapid assessment and management to prevent stroke. If symptoms persist or are fluctuating at the time of assessment the patient should be managed as a stroke, including immediate assessment for reperfusion therapy and hospital admission.

Diagnostic work-up and implementation of optimal therapy for patients with suspected TIA should be completed within 24 hours. This requires diagnostic confirmation by a stroke specialist, ECG +/- prolonged monitoring and brain imaging (CT or MRI). According to current definitions, the finding of an ischaemic lesion on brain imaging is classified as a stroke even if symptoms have fully resolved. Patients with ischaemic lesions on diffusion MRI are at substantially higher risk of recurrent ischaemic events. If anterior circulation symptoms are present, carotid imaging (ultrasound, CTA, or MRA) is also indicated. Optimal timing for carotid endarterectomy (if required) is within 2 weeks of symptom onset.

Where specialist assessment and/or diagnostic work-up for all suspected TIA patients is not feasible within the above recommended time frames, alternative providers, ideally with support from stroke specialists and/or risk stratification to focus treatment on those at highest risk, may be required. It is highly recommended that all services develop a local TIA pathway involving primary care, emergency department, and stroke specialist teams to ensure patients are managed as rapidly and comprehensively as possible matching locally available resources. Several highly effective TIA service models have been described to suit a variety of settings (Ranta and Barber 2016 [28]). Ongoing education around TIA for all involved providers is important. Smaller centres are encouraged to partner with larger services to assist with the establishment of such pathways.

Where GPs are confident about identifying all potential TIA's and have access to specialist assessment within 24 hours for all referred patients, it is unclear whether the use of a risk score adds clinical value and it is reasonable to rely on clinical assessment alone. In settings where GPs would benefit from diagnostic aid and/or where specialist review may be delayed by >1 day, the use of the stroke/TIA electronic decision support tool should be considered. If the tool is unavailable, but immediate access to a specialist cannot be guaranteed, the GP can use any one of the following criteria to identify patients who require immediate hospital referral: ongoing focal neurological symptoms, >1 TIA over past 7 days, presence of atrial fibrillation, patient treated with anticoagulants or ABCD² score >3. For any patients likely to access specialist assessment with >1 day delay the GP should initiate best medical therapy immediately (antiplatelet, antihypertensive, statin – anticoagulants require brain imaging before initiation) and counsel on smoking cessation and driving implications.

In the most recent clinical audit of stroke services in Australia, 102 out of 120–hospitals reported having defined and documented processes, policies or clinical pathways for assessing TIA patients (Stroke Foundation 2019 [7]). 33% of hospitals admitted all patients suspected of having TIA directly to hospitals, while 67% admitted only selected patients to hospitals (Stroke Foundation 2019 [7]). 29 hospitals had rapid assessment TIA clinics. Although the aim of the clinics is to assess and manage patients within 48 hours, the average waiting time for an appointment to a clinic was 3 days (Stroke Foundation 2019 [7]).

Strong recommendation

- All patients with suspected transient ischaemic attack (TIA), i.e. focal neurological symptoms due to focal ischaemia that have fully resolved, should have urgent clinical assessment. (Lavalley et al. 2007 [25]; Rothwell et al. 2007 [26]) (*Refer to the 'Practical Information' section for further useful information*)
- Patients with symptoms that are present or fluctuating at time of initial assessment should be treated as having a stroke and be immediately referred for emergency department and stroke specialist assessment, investigation and reperfusion therapy where appropriate. (Lavalley et al 2007 [25]; Rothwell et al. 2007 [26])
- In pre-hospital settings, high risk indicators (e.g. crescendo TIA, current or suspected AF, current use of anticoagulants, carotid stenosis or high ABCD² score) can be used to identify patients for urgent specialist assessment. (Lavalley et al. 2007 [25]; Rothwell et al. 2007 [26])

Practical Info

Distinguishing transient ischemic attack (TIA) from other presentations:

The most useful approach to appropriate resource allocation in the investigation of patients with suspected TIA is an accurate clinical diagnosis. Confident diagnosis of alternative causes for transient neurological symptoms will avoid unnecessary investigations and allow institution of appropriate management. If the most likely diagnosis is truly TIA then urgent investigation is

required (even if a risk stratification score such as ABCD² suggests “low risk”). Careful clinical assessment will also allow more targeted investigations (e.g. suspicion of posterior circulation TIA should lead to CT angiography as carotid Doppler will not adequately assess the posterior circulation).

TIA involves the sudden onset of a focal neurological deficit: weakness, numbness (not paraesthesia in isolation), visual loss, speech disturbance, etc. The average duration is approximately 10 minutes but all symptoms must be fully resolved within 24 hours. Carefully distinguishing dysphasia (language disturbance – incorrect word use or loss of comprehension) from dysarthria (poor articulation) is useful as dysphasia is specific and localising whereas dysarthria can be non-specific.

Common TIA mimics:

Migraine aura – can cause migratory neurological phenomena that move from one part of the body to an adjacent region over several minutes and these are often recurrent. “Positive” neurological symptoms are a key feature of migraine i.e. paraesthesia, visual flashes/blur, etc. Headache may be mild or absent but, if present, significantly reduces the probability of symptoms being due to TIA. While migraine aura may manifest as limb weakness or dysphasia, a first occurrence of these symptoms should prompt further investigation as for TIA.

Benign paroxysmal positional vertigo (BPPV) – isolated vertigo is very rarely ischaemic in origin (i.e. vertigo without associated ataxia, diplopia, dysarthria, numbness or weakness). “Dizzy” patients require careful questioning to distinguish the sense of motion that defines vertigo from non-specific light-headedness (which is not a feature of TIA). Brief, positionally provoked vertigo is usually due to BPPV and can be diagnosed and then treated with a Hallpike and Epley manoeuvre. Non-vertiginous dizziness often relates to blood pressure changes and is not an indication for carotid vascular imaging.

Transient global amnesia (TGA) – isolated anterograde amnesia with repetitive questioning, without loss of personal identity (which would indicate psychogenic fugue) and with otherwise normal neurological function generally indicates TGA rather than TIA. This is not associated with an increased risk of stroke.

Syncope – loss of consciousness and pre-syncope sensations in the absence of focal neurology should not be considered TIA. Although very rarely a basilar artery territory TIA could lead to loss of consciousness, there should be evidence of focal posterior circulation symptoms before or after the loss of consciousness e.g. diplopia, vertigo, weakness, or numbness. Patients with prior cerebrovascular disease who experience syncope can develop focal neurology after the event related to hypoperfusion. However, a focal presentation would generally require investigation as a TIA.

Hypoglycaemia – very low blood glucose levels occasionally lead to focal neurology in addition to more typical hypoglycaemic symptoms of diaphoresis and confusion and this should be considered in the differential diagnosis of TIA in diabetic patients taking medications that predispose them to hypoglycaemia.

Delirium – most episodes of delirium last too long to be a TIA. Delirium is characterised by altered attention/conscious state without focal neurology (apart from perhaps dysarthria) which is inconsistent with TIA. However, in patients with prior stroke, focal deficits may re-emerge and complicate assessment. Careful questioning is required to distinguish non-focal “confusion” (disorientation to time/place/person) from focal dysphasia or inattention that may be indicative of true TIA.

Amyloid “spells” – these events may perfectly mimic TIA but are often recurrent and stereotyped and may exhibit migrainous-like spread from one body region to another. They are due to cerebral amyloid angiopathy which can cause focal “convexal” subarachnoid haemorrhage. This is not associated with headache but can generate cortical spreading depression and migratory phenomena similar to migraine aura. CT brain (and preferably susceptibility-weighted MRI) is therefore essential to avoid harmful use of antithrombotics.

Focal seizure activity – seizures are usually distinguishable from TIA. “Positive” symptoms – clonic or myoclonic jerks, colourful/and or pulsating visual phenomena and migration of symptoms over seconds to 1–2 minutes are clinical clues. An unwitnessed seizure can be followed by Todd’s paresis (weakness, dysphasia, etc.) which may resolve over a time period similar to a TIA but is generally accompanied by a postictal drowsy and confused state with amnesia. Very occasionally, a TIA can present with limb shaking as a hypoperfusion phenomenon (e.g. critical carotid stenosis). These events usually have identifiable provoking factors that lead to drops in BP (changes in posture, blood pressure lowering medication, heavy meal, etc.) and do not involve the face.

Functional disorders – these can be challenging but more often present with ongoing symptoms and therefore enter the differential diagnosis of stroke more than TIA. “Collapsing” weakness and positive Hoover’s sign are useful if examined during the event. Symptoms of dissociation (“out of body” or “loss of contact”) and bilateral extremity paraesthesia (hyperventilation) may be useful.

Evidence To Decision

Benefits and harms

Substantial net benefits of the recommended alternative

The risk of stroke is greatest in the first few hours and days after a TIA. Two studies in UK and France using historical controls reported an 80% risk reduction in recurrent stroke at 90 days when rapid access clinics to assess, investigate and initiate intensive secondary prevention medications were established (Lavalley et al. 2007 [25]; Rothwell et al. 2007 [26]). There were no harms identified.

Certainty of the Evidence

Moderate

The evidence is largely based on non-randomised studies comparing stroke incidence following TIA before and after implementing rapid access TIA management or comparing outcomes to historical controls (Lavalley et al. 2007 [25]; Rothwell et al. 2007 [26]). This introduces a potential risk of bias that could result in overestimation of the treatment effect without accounting for other factors that may have reduced post-TIA stroke risk over recent years (e.g. more widespread use of cardiovascular risk management at baseline), and the comparators may not represent the true baseline rate of recurrent stroke. However, the large size of effect makes us moderately confident that it was effective in reducing recurrent stroke.

Values and preferences

Substantial variability is expected or uncertain

Some patients may prefer to be managed by their general practitioner closer to home or may experience barriers to rapidly accessing specialists. This needs to be considered when designing local patient focussed services, keeping in mind that the best evidence available does indicate that outcomes are optimised if early specialist or specialist assisted assessment is achieved.

Resources and other considerations

No important issues with the recommended alternative

Resources considerations

There is evidence from a single centre study conducted in Australia that non-admission based care with follow-up in an outpatient clinic was more effective in terms of strokes prevented and cost-saving compared to admission-based care for patients presenting to the emergency department with suspected TIA (Sanders et al. 2015 [29]).

Implementation consideration

There are organisational indicators collected in the National Stroke Audit on whether hospitals have defined and documented processes, policies or clinical pathways for assessing suspected TIA patients. Organisational indicators are also collected on whether all, or only selected, TIA patients are admitted to hospital.

Rationale

Transient ischaemic attacks (TIA) are predictors for subsequent stroke. The risk of stroke is greatest in the first few hours and days after a TIA. The high risk of disabling and fatal stroke within a few days of a TIA is the basis for recommending urgent intervention. This means that patients with potential TIA should be medically assessed as soon as they present and those with symptoms consistent with TIA investigated promptly. If not immediately available, investigations should be completed within 2 days. Two non-randomised studies showed rapid assessment and management of TIA patients could potentially reduce recurrent stroke (Lavalley et al. 2007 [25]; Rothwell et al. 2007 [26]).

Clinical Question/ PICO

Population: All adults with suspected TIA
Intervention: Rapid assessment and treatment
Comparator: Control

Summary

One UK study (EXPRESS) measured the rate of recurrent stroke before and after the set-up of a TIA clinic, in which patients with suspected TIA were immediately assessed and treated (Rothwell et al. 2007 [26]). The 90-day risk of recurrent stroke in

the patients referred to the study clinic was 10.3% (32/310 patients) before the clinic and 2.1% (6/281 patients) after (adjusted hazard ratio 0.20, 95% CI 0.08-0.49; p=0.0001). The reduction in risk was independent of age and sex, and early treatment did not increase the risk of intracerebral haemorrhage or other bleeding. A French study (SOS-TIA) set up a 24/7 rapid TIA clinic attached to a large urban stroke unit hospital (Lavalée et al. 2007 [25]). They also found an 80% reduction in 90-day recurrent stroke rate compared to that predicted by the ABCD² tool (1.24% actual vs 5.96% expected risk).

Both studies have high methodological quality but it is questionable if the comparators represent the true rate of recurrent stroke in the population. On the other hand, the large scale of risk reduction still shows that rapid assessment and treatment is likely to be beneficial for patients with suspected TIA.

Outcome Timeframe	Study results and measurements	Comparator Control	Intervention Rapid assessment and treatment	Certainty of the Evidence (Quality of evidence)	Plain language summary
Recurrent stroke 90 days 8 Critical	Based on data from 2,357 participants in 2 studies. (Observational (non-randomized)) Follow up: 90 days.	Two non-randomised studies evaluated rapid assessment and treatment of TIA and both found significant reduction of recurrent stroke of around 80%.		Moderate Potential risk of bias, and upgraded due to Very large magnitude of effect ¹	Rapid assessment and management of suspected TIA patients probably reduces recurrent stroke

1. **Risk of Bias: serious.** For observational studies, these two have high methodological quality; the comparator was recurrent stroke rate before the intervention, and recurrent stroke predicted by ABCD2 which may introduce confounding. **Inconsistency: no serious.** **Indirectness: no serious.** **Imprecision: no serious.** **Publication bias: no serious.** **Upgrade: very large magnitude of effect.**

Attached Images

Strong recommendation

When TIA patients present to primary care, the use of TIA electronic decision support, when available, is recommended to improve diagnostic and triage decisions. (Ranta et al. 2015 [15])

Practical Info

Stroke/TIA decision support tool

The evidence-based Stroke/TIA decision support tool referred to in the new Stroke Guidelines is provided by BPAC Clinical Solutions. BPAC Clinical Solutions has been developing health informatics software for primary care, designed specifically to support health practitioners in the management of patients. BPAC Clinical Solutions' clinically led team has pioneered a range of proven solutions, including screening, risk assessment and management, referrals, and analytics, and these are fully integrated into the existing workflow and clinical software, ensuring a seamless user experience.

The Stroke/TIA integrated decision support tool has been available to GP practices around New Zealand since its national launch in July 2015. Approximately 1000 practices now have access to the module and it has been used to assist clinician decision-making for over 1800 patients to date.

The tool consists of a data entry form and an expert-generated guideline-based computer algorithm. The tool provides diagnostic help, triage advice, and prompts immediate prescription of best medical therapy.

A three-minute instructional video demonstrating the functionality available in the New Zealand tool can be watched at www.bestpractice.net.nz/stroke-tia

Australia

BPAC Clinical Solutions is aiming to release the Stroke/TIA integrated clinical decision support tool in Australia but it is not formally available (at May 2022). However, a demonstration site is available at https://www.bestpractice.org.nz/TIA_Demo.asp. BPAC Clinical Solutions already delivers electronic referrals in Australia via its SeNT (Secure Electronic Network Transfer) project in Queensland, New South Wales and Victoria. BPAC Clinical Solutions has been integrated with a number of GP software systems in Australia as well as HHS software providers, and is linked with Health Pathways. Depending on the GP practice software, the module will be launched in the context of the selected patient in the practice software and pre-populate with relevant information from the patient's medical record.

Evidence To Decision

Benefits and harms

Substantial net benefits of the recommended alternative

TIA electronic decision support is intended to assist primary care providers in optimising early assessment and management of patients with TIA and stroke. Use of the tool improves guideline adherence and reduces secondary stroke (30 per 1000) without increasing adverse events (Ranta et al. 2015 [15]).

Certainty of the Evidence

Moderate

This evidence is based on a cluster randomised controlled trial; the only randomised controlled trial in the TIA literature around optimising patient management in primary care (Ranta et al. 2015 [15]). There are some methodological limitations related to the cluster design and moderate sample size.

Values and preferences

Substantial variability is expected or uncertain

It is very likely that patients prefer being managed in accordance with guidelines and having the reassurance that a TIA diagnosis is not overlooked by their GP. In addition, some patients may prefer comprehensive management in primary care avoiding hospital referral if a TIA diagnosis is unlikely or even if a diagnosis is confirmed in a setting where specialist access is challenging and the general practitioner can access all of the required interventions. Other patients may prefer having the reassurance of being assessed by a specialist for potential TIA regardless of the likelihood of this concern being justified.

Resources

No important issues with the recommended alternative

Resources considerations

There is evidence that TIA electronic decision support in primary care is cost-saving, with average costs per patient being NZ\$1,470 lower in supported clinics than in clinics not provided with this support (cost reference year 2012) (Ranta et al. 2014 [15]).

Rationale

Only one cluster randomised controlled trial investigated decision support tools in primary care to improve patient outcomes, and it was shown to significantly reduce stroke occurrence with no increase in adverse events (Ranta et al. 2015 [15]). Moreover, most of the patients would prefer to have their potential TIA managed in accordance with best-practice guidelines.

The decision support tool included in the RCT is available throughout New Zealand but is currently not available in Australia.

Clinical Question/ PICO

Population:	All adults with suspected TIA in primary care setting
Intervention:	Decision support tool
Comparator:	Confirmed diagnosis of recurrent stroke

Summary

The study on an electronic decision support tool from Ranta et al. (2015) [15] is the only randomised controlled trial on this topic. It provides moderate evidence on a safe and potentially effective tool in reducing stroke occurrence when used in the primary care setting.

Our literature search identified a number of studies on diagnostic performance of TIA recognition tools but none of them showed superior performance. The Dawson score (Lassersen et al. 2015 [16]) achieved high sensitivity of 92.3% but low specificity of 18.1% in 513 suspected TIA referrals from primary care. However, it was retrospectively assessed by a research team based on primary care referral notes which may not reflect the accuracy when used prospectively by primary care clinicians. The assessors were not blinded either, which raises concerns for detection bias. Sung et al (2011) [18] assessed six symptom-related questions on The Questionnaire for Verifying Stroke-Free Status (QVSS) in 155 patients referred from secondary services. The sensitivity of answering 'yes' to at least one of any of the six symptom questions was 0.82, and the specificity was 0.62. However, it has similar issues of detection bias and directness of evidence. Clarey et al. (2014) [17] calculated the absolute cardiovascular risk (ACVR) score for 179 participants presenting as possible TIA and minor stroke in Australian general practices. They did not find improved diagnostic accuracy of ACVR beyond that of age and sex.

Outcome Timeframe	Study results and measurements	Comparator Confirmed diagnosis of recurrent stroke	Intervention Decision support tool	Certainty of the Evidence (Quality of evidence)	Plain language summary
Occurrence of stroke 90 days 8 Critical	Odds ratio 0.27 (CI 95% 0.05 – 1.41) Based on data from 291 participants in 1 studies. ¹ (Randomized controlled) Follow up: 90 days.	42 per 1000 Difference:	12 per 1000 30 fewer per 1000 (CI 95% 40 fewer – 16 more)	Moderate Some imprecision and possible risk of bias ²	TIA decision support tool probably decreases occurrence of stroke
Adverse events ³ 7 Critical	Odds ratio 1.25 (CI 95% 0.48 – 3.24) Based on data from 291 participants in 1 studies. (Randomized controlled)	42 per 1000 Difference:	52 per 1000 10 more per 1000 (CI 95% 21 fewer – 82 more)	Moderate Due to serious risk of bias ⁴	TIA recognition tool in primary care probably has little or no difference on adverse events

1. Primary study[15]. **Baseline/comparator:** Control arm of reference used for intervention.
2. **Risk of Bias: no serious.** Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Inconsistency: no serious.** **Indirectness: no serious.** **Imprecision: serious.** Only data from one study, Wide confidence intervals. **Publication bias: no serious.**
3. Any event in which the tool's diagnosis or triage recommendations may have adversely affected patients.
4. **Risk of Bias: serious.** Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Inconsistency: no serious.** **Indirectness: no serious.** **Imprecision: no serious.** Wide confidence intervals and only one study, but the this outcome is less critical: all adverse events were from medication side effects and reversible. **Publication bias: no serious.**

Attached Images

Weak recommendation against

Updated evidence, no change in recommendation

In TIA patients, use of the ABCD² risk score in isolation to determine the urgency of investigation may delay recognition of atrial fibrillation and symptomatic carotid stenosis in some patients and should be avoided. (Wardlaw et al. 2015 [8])

Evidence To Decision

Benefits and harms

Small net benefit, or little difference between alternatives

Several risk scores have been proposed to stratify the risk of recurrent ischaemic events and have sometimes been used as a means of prioritising the urgency of investigation for TIA. However, studies have indicated that the most commonly used risk score (ABCD²) and its more recent adaptations (e.g. ABCD³ and ABCD³-I) classify an important proportion of TIA patients with atrial fibrillation and symptomatic carotid stenosis in the "low risk" category, potentially exposing them to detrimental treatment delays and risk of recurrent ischaemic events (Wardlaw et al. 2015 [8]; Sanders et al. 2012 [9]; Galvin et al. 2011 [10]; Merwick et al. 2010 [24]).

Certainty of the Evidence

Moderate

Moderate quality of evidence from multiple systematic reviews of observational studies with large sample size reporting similar results (downgraded for statistical heterogeneity).

Values and preferences

No substantial variability expected

Areas of major debate

Some clinicians argue that risk stratification tools have such low utility they should not be used when appropriate referrals and subsequent specialist assessments can be made. However, others believe they have value in supporting primary care physicians' decision-making when considered along with other high risk indicators.

Resources and other considerations

No important issues with the recommended alternative

Resources considerations

No literature to understand or describe the potential economic implications of this recommendation was identified.

Implementation considerations

There is an organisational indicator collected in the National Stroke Audit on whether patient selection for admission incorporates one of the published TIA risk stratification scores.

Rationale

Risk stratification in TIA patients has been used in the past in an attempt to prioritise rapid investigation of high-risk patients in settings with limited resources. However, approximately 25% of patients classified as "low risk" for recurrent ischaemic events by ABCD² have atrial fibrillation or symptomatic carotid stenosis which requires an important change in management (Wardlaw et al. 2015 [8]; Sanders et al. 2012 [9]; Galvin et al. 2011 [10]).

The major challenge in TIA is diagnostic specificity, i.e. ensuring that resources are appropriately focused on patients likely to have true ischaemic aetiology rather than non-specific symptoms. Inclusion of dual events and brain imaging can improve scores, however, availability of rapid (same day) MRI is very limited in most hospitals and not available in general practice, thus involving the local stroke specialist or electronic decision support tool that guides assessment and decision making is preferred over any derivative of the ABCD tool. There may be some role for clinical scores to improve diagnostic accuracy in settings that lack rapid access to specialist assessment.

In the environment of immediate assessment in an emergency department or dedicated TIA clinic, investigation of patients with true TIA should occur immediately and prioritisation is not relevant.

Clinical Question/ PICO

Population:	All adults with suspected TIA
Intervention:	Risk prediction scores
Comparator:	Confirmed diagnosis of recurrent stroke

Summary

There are a number of risk prediction tools in the literature. Perry et al. (2014) [13] prospectively enrolled and analysed 3906 patients, and derived a Canadian TIA score that consists of 13 variables. They reported a c-statistic of 0.77 (95% confidence interval, 0.73–0.82) for prediction of subsequent stroke within 7 days (c-statistics indicate discrimination better than chance at >0.5). Perry et al. (2021)[88] subsequently also compared the Canadian TIA score with ABCD² and ABCD²i in 7607 participants. The difference in the C statistic for subsequent stroke or carotid revascularisation within seven days was 0.10 (95% CI 0.05 to 0.15) when comparing Canadian TIA score with ABCD² and 0.06 (95% CI 0.01 to 0.11) with ABCD²i. The area under the curve for the Canadian TIA Score (0.7, 95% CI 0.66 to 0.73) was higher than that of the ABCD² (0.60, 95% CI 0.55 to 0.64) or ABCD²i (0.64, 95% CI 0.59 to 0.68) score but is still low to be routinely relied on in clinical practice. Arsava et al. (2011) [14] calculated used a Web-based stroke recurrence estimator (<http://www.nmr.mgh.harvard.edu/RRE/>) in a retrospective series of 257 patients and found the sensitivity and specificity of a score of ≥ 2 for predicting 7-day stroke risk were 87% and 73%, respectively.

ABCD² is by far the most extensively studied risk prediction score for recurrent stroke in adults with suspected TIA. A meta-analysis of 13,766 TIA patients from 29 studies showed that the ABCD² score probably did not reliably discriminate those at low and high risk of recurrent stroke, and did not identify patients with carotid stenosis or AF needing urgent intervention (Wardlaw et al. 2015 [8]). Other systematic reviews came to similar conclusion. Sanders et al. (2012) [9] found a high sensitivity of 0.89 (0.87–0.91) and low specificity of 0.34 (0.33–0.35) for the cutoff value of 4. At 5% baseline stroke risk, ABCD² > 3 indicated an absolute increase in 7-day stroke risk of only 2.0% while a score equal or less than 3 indicated a 2.9% decrease in risk. Galvin et al. (2011) [10] also indicated over-prediction of recurrent stroke in all risk categories at 90 days.

Merwick et al. (2010) [24] proposed an ABCD³ score based on preclinical information and ABCD³-I based on imaging and other secondary care assessments. N = 2654 patients were included in the derivation sample and 1232 in the validation sample. ABCD³ score (range 0–9 points) was derived by assigning 2 points for dual transient ischaemic attack (an earlier transient ischaemic attack within 7 days of the index event). C statistics for the ABCD³ score were 0.78 at 2 days, 0.80 at 7 days, 0.79 at 28 days, and 0.77 at 90 days, compared with C statistics for the ABCD² score of 0.71 at 2 days (p=0.083), 0.71 at 7 days (p=0.012), 0.71 at 28 days (p=0.021), and 0.69 at 90 days (p=0.018). Stenosis of at least 50% on carotid imaging (2 points) and abnormal DWI (2 points) were added to the ABCD³-imaging (ABCD³-I) score (0–13 points). Note that with the change in definition of TIA these DWI positive patients would now be diagnosed as having a minor stroke. C statistics for the ABCD³-I score were 0.90 at 2 days (compared with ABCD² score p=0.035), 0.92 at 7 days (p=0.001), 0.85 at 28 days (p=0.028), and 0.79 at 90 days (p=0.073). The 90-day net reclassification improvement compared with ABCD² was 29.1% for ABCD³ (p=0.0003) and 39.4% for ABCD³-I (p=0.034).

Kelly et al. (2016)[86] in a pooled analysis of 16 cohort studies (n=2176) found similar C statistics for ABCD³-I score and for ABCD²-I: 0.74 (95% CI 0.67 to 0.80) at 2 days (compared with ABCD² score p=0.006), 0.71 at 7 days (95% CI 0.64 to 0.77; p< 0.001), 0.70 at 28 days (95% CI 0.64 to 0.77; p< 0.001), and 0.71 at 90 days (95% CI 0.65 to 0.76; p< 0.001), showing both ABCD²-I and ABCD³-I scores have better predictive ability than ABCD² score with ABCD³-I better than ABCD²-I. Positive DWI (OR 3.8, 95%CI 2.1 to 7.0), dual TIA (OR 3.3, 95%CI 1.8 to 5.8) and ipsilateral carotid stenosis (OR 4.7, 95%CI 2.6 to 8.6) were all significantly associated with stroke within 7 days.

A review by Zhao et al. (2017)[87] pooled data from 6 studies (n=7364) that compared the diagnostic accuracies of ABCD² and ABCD³-I for predicting future stroke. ABCD³-I scores had better sensitivity at 7 days (96.1%, 95% CI 90.2 to 98.5 vs 79.9%, 95% CI 62.2 to 90.6) and 90 days (94.6%, 95% CI 88.9 to 97.5 vs 76.6%, 95% CI 63.8 to 85.8) but poorer specificity (7 days: 17.7%, 95% CI 8.5 to 33.3 vs 29.2%, 95% CI 18.2 to 43.3; 90 days: 20.2%, 12.6 to 30.6 vs 40.3%, 25.0 to 57.7) than ABCD² scores. The review suggested physicians should not entirely rely on risk scores for clinical decision making and that it may be more appropriate to carefully consider each of the components of the scores rather than using dichotomised scoring during clinical triage.

Outcome Timeframe	Study results and measurements	Comparator Confirmed diagnosis of recurrent stroke	Intervention Risk prediction scores	Certainty of the Evidence (Quality of evidence)	Plain language summary
Prediction of stroke 7 days, 90 days or greater	Based on data from 13,766 participants in 29 studies. (Observational (non-randomized)) Follow up: more than 90 days.	The sensitivity of the ABCD ² score equal or greater than 4 to predict stroke was 86.7 (95% CI 81.4–90.7) at 7 days and 85.4 (95% CI 81.1–88.9) at 90 days; specificity was 35.4 (95% CI 33.3–38.3) at 7 days and 36.2 (95% CI		Moderate Due to serious inconsistency ¹	The ABCD ² score probably does not reliably discriminate those at low and high risk of recurrent stroke, or identify patients with carotid

Outcome Timeframe	Study results and measurements	Comparator Confirmed diagnosis of recurrent stroke	Intervention Risk prediction scores	Certainty of the Evidence (Quality of evidence)	Plain language summary
7 Critical		34.0–37.6) at 90 days. Additionally, 20% of patients with ABCD2 <4 had >50% carotid stenosis or atrial fibrillation (AF).			stenosis or AF needing urgent intervention

1. **Risk of Bias: no serious.** Methodological quality of included studies varies but mostly high quality diagnostic studies..
Inconsistency: serious. The magnitude of statistical heterogeneity was high, with $I^2 > 90\%$..
Indirectness: no serious.
Imprecision: no serious. Publication bias: no serious.

Attached Images

Strong recommendation

All TIA patients with anterior circulation symptoms should undergo early carotid imaging with CT angiography (aortic arch to cerebral vertex), carotid Doppler ultrasound or MR angiography. Carotid imaging should preferably be done during the initial assessment but should not be delayed more than 2 days (see [Imaging](#)).

Rationale

In TIA patients, early cerebrovascular imaging (CTA or MRA from aortic arch to cerebral vertex) is indicated. The presence of vascular stenosis or occlusion helps distinguish true ischaemic events from mimics and places these patients in the highest risk category for recurrent events and symptom progression (Coutts et al. 2012 [21]). It may also guide intensive secondary prevention (e.g. dual antiplatelets for those with significant intracranial stenoses) (Kamal et al. 2015 [27]).

As a minimum requirement, carotid imaging for patients with carotid territory TIA (e.g. Doppler ultrasound) is essential to identify symptomatic carotid lesions, as patients with TIA and carotid stenosis of at least 50% ipsilateral to the involved brain tissue should be considered for carotid endarterectomy.

Timely assessment is important as the risk of recurrent stroke or stroke progression is highest in the first few hours to days after TIA or minor stroke. Carotid endarterectomy is most effective when performed early (see [Carotid surgery](#) in the Secondary Prevention chapter). Urgent investigation may be facilitated by management in an emergency department or dedicated TIA clinic. When patients have presented in a delayed manner, investigation within 2 days may be acceptable.

Weak recommendation

Patients with TIA should routinely undergo brain imaging to exclude stroke mimics and intracranial haemorrhage. MRI, when available, is recommended to improve diagnostic accuracy (see [Imaging](#)).

Rationale

The importance of brain imaging in TIA has been controversial as it affects management only in a minority of patients. However, improved diagnostic and prognostic accuracy, reassurance of absence of a cerebral haemorrhage (including focal subarachnoid bleeding related to amyloid angiopathy as a cause of transient symptoms) and exclusion of mimics are important in any setting, and therefore brain imaging is recommended. Where anticoagulation is being considered, brain imaging is especially important given the greater risk of intracerebral haemorrhage. When available, MRI has greater sensitivity and specificity in this patient population.

Strong recommendation

Patients with suspected TIA should commence secondary prevention therapy urgently (see [Secondary Prevention](#)).

Rationale

Any delay in the initiation in secondary prevention has been associated with worse patient outcomes in the form of a higher rate of early stroke recurrence and thus it is recommended that all relevant secondary preventive medications are started as soon as possible, even though the diagnosis may still carry some degree of uncertainty. The only exception is anticoagulant therapy, which requires a head CT scan before such therapy is instituted to exclude an intracerebral haemorrhage (Rothwell et al. 2007 [26]).

Strong recommendation

- All patients with TIA should be investigated for atrial fibrillation with ECG during initial assessment and referred for possible prolonged cardiac monitoring as required (see [Cardiac Investigations](#)).
- TIA patients with atrial fibrillation should commence anticoagulation therapy early after brain imaging has excluded haemorrhage, unless contraindicated (see [Anticoagulant therapy](#) in [Secondary Prevention](#)).

Rationale

The detection of atrial fibrillation in TIA patients is important to maximise secondary stroke prevention. Where atrial fibrillation is identified, prescription of anticoagulation has been associated with significant reduction in subsequent stroke.

Good practice statement**Consensus-based recommendations**

- All patients and their family/carers should receive information about TIA, screening for diabetes, tailored advice on lifestyle modification strategies (smoking cessation, exercise, diabetes optimisation if relevant – see [Secondary prevention](#)), return to driving (see [Driving](#) in [Community participation and long-term care](#)) and the recognition of signs of stroke and when to seek emergency care.
- All health services should develop and use a local TIA pathway covering primary care, emergency and stroke specialist teams to ensure patients with suspected TIA are managed as rapidly and comprehensively as possible within locally available resources.

Rationale

Behavioural counselling on diabetic control and diet, exercise and smoking cessation are important components of secondary stroke prevention following TIA and should be incorporated in all management plans. Written information can help provide the patient more detailed information and can also reiterate the importance of seeking care urgently should symptoms recur. Driving restrictions apply following a TIA and need to be clearly communicated to patients to minimise risks of injury to self and others.

TIA management can be complex and routinely involves many providers across several sectors. The better coordinated these services are across this continuum, the faster and more effectively patients can access best medical care minimising the risk of secondary stroke. In addition, different environments face different geographic, logistic, and resource challenges. All of these factors should be considered when implementing a comprehensive, cohesive, well-coordinated, and locally tailored TIA service to best meet the area's population needs and achieve the best patient outcomes.

Assessment of suspected stroke

Initial clinical assessment remains the cornerstone in the diagnosis of stroke and TIA. Further investigations and brain imaging are undertaken to confirm the diagnosis and are essential for a decision on intervention, but the initial assessment at a minimum determines whether the patient has acute, focal or neurological deficits.

There are a number of clinical assessment tools available for emergency department staff, such as ROSIER, FAST and NIHSS. The reliability of assessment tools improves with experience and confidence, suggesting the need for a close working relationship between emergency department staff and stroke specialists, and the development of rapid referral processes.

The use of blood biomarkers for diagnostic purposes has been studied, however the evidence is inadequate to support their use in place of imaging to confirm the diagnosis of stroke and differentiate ischaemic stroke from intracerebral haemorrhage (An et al. 2013 [35]; Whiteley et al. 2011 [36]; Vanni et al. 2011 [37]). With the advent of effective endovascular therapy for patients with large artery occlusion, there has also been growing interest in clinical scales to identify patients likely to have large vessel occlusion. However, no clinical scale has adequate diagnostic performance for this purpose (Turc et al. 2016 [30]; Perez 2014 [32])

According to the most recent clinical audit of stroke patients, 113 out of 120 hospitals reported having emergency department protocols for rapid triage for patients presenting with acute stroke, and 52% of patients were assessed in the emergency department (Stroke Foundation 2019 [7]).

Strong recommendation

All suspected stroke patients who have been pre-notified to the stroke or ED team, and who may be candidates for reperfusion therapy, should be met at arrival and assessed by the stroke team or other experienced personnel. (Meretoja et al. 2012 [40]; Meretoja et al. 2013 [39])

Evidence To Decision

Benefits and harms

Substantial net benefits of the recommended alternative

A rapid assessment protocol in a Helsinki hospital reduced median door-to-needle time from 105 minutes to 20 minutes, and achieved a thrombolysis rate of 31% (Meretoja et al. 2012 [40]). It was applied to an Australian hospital and reduced door-to-needle time from 61 minutes to 46 minutes despite only being implemented during business hours (Meretoja et al. 2013 [39]). Considering the current thrombolysis rate of 8% and door-to-needle time of 78 minutes in Australia (Stroke Foundation 2015 [7]), the intervention is likely to substantially improve the current practice.

Certainty of the Evidence

Moderate

The evidence is based on two well-designed non-randomised studies (Meretoja et al. 2012 [40]; Meretoja et al. 2013 [39]). Although a randomised controlled trial is ideal, the certainty in effect estimate is considered to be moderate due to the large improvement and sample size.

Values and preferences

No substantial variability expected

Patients are likely to want to receive rapid assessments since it has potential benefits and no harms.

Resources and other considerations

No important issues with the recommended alternative

Resources considerations

No literature to understand or describe the potential economic implications of this recommendation was identified.

Implementation consideration

There is a clinical indicator collected on whether patients were screened in the emergency department using a validated tool. This clinical indicator is included in the Acute Stroke Clinical Care Standard, specifically excluding patients who were in-hospital

strokes, inter-hospital transfers or unconscious. Additionally, an organisational indicator is collected on whether hospitals have emergency department protocols in place for rapid triage of patients presenting with acute stroke.

Rationale

Early reperfusion therapies have been proven to improve patients' outcomes (see section Thrombolysis in chapter Acute Medical and Surgical Management). A protocol of rapid assessment after pre-notification to the emergency department in a Helsinki hospital (Meretoja et al. 2012 [40]) reduced door-to-needle time and reached a thrombolysis rate of 31% (compared to 8% in the most recent clinical audit data in Australia (Stroke Foundation 2015 [7])). This protocol was then successfully applied to an Australian hospital (Meretoja et al. 2013 [39]).

Clinical Question/ PICO

- Population: Adults with suspected stroke
- Intervention: Rapid management
- Comparator: Usual care

Summary

Meretoja et al. (2012) [40] reported the results of interventions to reduce treatment delays for stroke patients treated with intravenous alteplase. From 1998 to 2011, ischaemic stroke patients treated with alteplase at a Helsinki hospital were prospectively registered and followed up at 3 months. During this period, 12 measures for reducing treatment delays were gradually introduced, including high priority dispatch, pre-notification, relocation of CT to the emergency room, and delivery of alteplase treatment on the CT table. CT scans were interpreted by stroke physicians without waiting for radiology reports, with advanced imaging only conducted when uncertainty was present. Door-to-needle times (for non-basilar artery occlusion patients) were reduced throughout the study period, from an initial median of 105 minutes to 20 minutes in 2011. 31% of ischaemic stroke patients were treated with alteplase in 2011. However, patients not eligible for alteplase treatment were admitted to other hospitals in the province, meaning the overall alteplase treatment rate for the province was 16%.

Based on these results, Meretoja et al. (2013) [39] attempted to apply the same protocol at the Royal Melbourne Hospital. Stroke and stroke mimic patients were prospectively registered in the Royal Melbourne Hospital Stroke Registry between 2003 and 2012. Applicable elements of the Helsinki model were introduced during office hours (8 am to 5 pm Monday to Friday) beginning in May 2012, with out-of-hours care remaining the same. Elements of the Helsinki model introduced included pre-notification of the stroke team, patients going directly to CT on ambulance stretchers after a brief assessment of cardiorespiratory stability, and initiating alteplase treatment on the CT table. Other elements were modified due to differences between the original Helsinki hospital and the Royal Melbourne setting, such as registering patient details and calling the GP before arrival due to the lack of electronic patient records. Door-to-needle times significantly decreased from 2011 (median 61 minutes) to 2012 (median 46 minutes), driven by the in-hours door-to-needle time, which decreased significantly from 43 to 25 minutes. The study authors concluded that reductions in door-to-needle time should be possible in a variety of settings by attempting to do as much preparation as possible before patient arrival.

Gelecio-Castillo et al (2022) [113] reviewed 12 studies (n = 2,890) comparing outcomes of large vessel occlusion stroke patients following the direct to angiosuite (DTAS) strategy versus standard workflow (SW) when undergoing endovascular therapy. DTAS strategy was associated with significantly higher odds of good functional outcome (OR 1.58, 95% CI: 1.16 to 2.14), significant reductions of door-to-puncture times (MD = -35.09 minutes, 95% CI: -49.76 to -20.41) and significant reductions of door-to-reperfusion times (MD = -32.88 minutes, 95% CI: -50.75 to -15.01) compared to SW. No differences were found in symptomatic intracranial hemorrhage, mortality or successful reperfusion rates. DTAS was also associated with greater odds of dramatic clinical improvement at 24 hours (OR 1.79, 95% CI: 1.15 to 2.79).

Outcome Timeframe	Study results and measurements	Comparator Usual care	Intervention Rapid management	Certainty of the Evidence (Quality of evidence)	Plain language summary
Functional Outcome at 90 days	Odds ratio 1.58 (CI 95% 1.16 – 2.14) Based on data from 1,911 participants in 6 studies. ¹	349 per 1000	459 per 1000	Very low Due to serious risk of bias, Due to serious	Rapid management may improve functional outcome at 90 days.

Outcome Timeframe	Study results and measurements	Comparator Usual care	Intervention Rapid management	Certainty of the Evidence (Quality of evidence)	Plain language summary
9 Critical	(Randomized controlled)	Difference:	110 more per 1000 (CI 95% 34 more – 185 more)	inconsistency, Due to serious publication bias ²	
Dramatic clinical improvement at 24 hours	Odds ratio 1.79 (CI 95% 1.15 – 2.79) Based on data from 675 participants in 3 studies. ³ (Randomized controlled)	317 per 1000 Difference:	454 per 1000 137 more per 1000 (CI 95% 31 more – 247 more)	Low Due to serious risk of bias, Due to serious inconsistency ⁴	Rapid management may improve dramatic clinical improvement at 24 hours.
9 Critical					

1. Systematic review [113] . **Baseline/comparator:** Systematic review [113] .
2. **Risk of Bias: serious.** Inadequate sequence generation/ generation of comparable groups, resulting in potential for selection bias, Trials stopping earlier than scheduled, resulting in potential for overestimating benefits. **Inconsistency: serious.** The magnitude of statistical heterogeneity was medium, with $I^2:40\%$. **Indirectness: no serious.** **Imprecision: no serious.** **Publication bias: serious.** Known/suspected unfunded/incomplete Studies.
3. Systematic review [113] . **Baseline/comparator:** Systematic review [113] .
4. **Risk of Bias: serious.** Inadequate sequence generation/ generation of comparable groups, resulting in potential for selection bias. **Inconsistency: serious.** The magnitude of statistical heterogeneity was medium, with $I^2:40\%$. **Indirectness: no serious.** **Imprecision: no serious.** **Publication bias: no serious.**

Attached Images

Weak recommendation

Updated evidence, no change in recommendation

The use of clinical screening tools to identify stroke by ED staff is recommended where an expert stroke team is unable to immediately assess a patient. (Zhelev et al. 2019[105])

Evidence To Decision

Benefits and harms

Small net benefit, or little difference between alternatives

Stroke screening tools may be useful in the initial, rapid identification of acute stroke patients. In the hospital ED setting the ROSIER scale has good sensitivity but lower sensitivity but is the preferred tool. The CPSS is suggested in prehospital settings. (Zhelev et al 2019[105])

Certainty of the Evidence

Moderate

The overall quality of evidence is moderate for ROSIER.

Values and preferences

No substantial variability expected

Despite a moderate diagnostic performance, clinical screening tools are likely to be preferred by suspected stroke patients to assist rapid identification when an expert stroke team is not immediately available.

Resources and other considerations

Important issues, or potential issues not investigated

Resources considerations

No literature to understand or describe the potential economic implications of this recommendation was identified.

Rationale

Stroke screening tools can assist in the identification of stroke in the initial ED assessment. FAST and ROSIER have been validated and are suggested with the ROSIER preferred given the larger number of studies although there was no statistically significant difference in sensitivities and specificities between them.

Clinical Question/ PICO

Population: Adults with suspected stroke
Intervention: Stroke screening tool
Comparator: Confirmed diagnosis

Summary

A Cochrane review by Zhelev et al. (2019)[105] investigated stroke recognition scales. Study level sensitivity and specificity ranges were provided when heterogeneous results were present. The Recognition of Stroke in the Emergency Room (ROSIER; 8 studies, n= 2895) scale had a summary sensitivity of 0.88 (95% CI 0.84 to 0.91) and study level specificity range of 0.18 to 0.93 (based on 5 studies, all in ED). Two of the studies had high risk of bias or applicability concerns. The Cincinnati Prehospital Stroke Scale (CPSS; 11 studies, n= 4157) had a sensitivity range of 0.44 to 0.95 and specificity range of 0.21 to 0.79. Nine studies had high risk of bias or applicability concerns. Face Arm Speech Time (FAST; five studies, n= 1894) had sensitivity of 0.64 to 0.97, specificity of 0.13 to 0.92 and 3 studies of high risk of bias or applicability concerns. The Los Angeles Prehospital Stroke Scale (LAPSS; 5 studies, n= 1794) had sensitivity of 0.83 (95% CI 0.75 to 0.89), specificity of 0.93 (95% CI 0.88 to 0.96) and 4 studies at high risk of bias or applicability concerns. The Melbourne Ambulance Stroke Scale (MASS; three studies, n= 981) had a sensitivity of 0.74 to 0.90, specificity of 0.67 to 0.86 and 3 studies with high risk of bias or applicability concerns. The Ontario Prehospital Stroke Screening Tool (OPSST; one study, n= 554) had a sensitivity of 0.92 (95% CI 0.88 to 0.94), specificity of 0.86 (95% CI 0.80 to 0.90) but has high risk bias or applicability concerns. From one study with 416 participants and at high risk of bias or applicability concern, the Medic Prehospital Assessment for Code Stroke (MedPACS) scale had a sensitivity of 0.74 (95% CI 0.67 to 0.80), specificity of 0.33 (95% CI 0.27 to 0.39). The PreHospital Ambulance Stroke Test (PreHAST) analysed from one study and 69 participants had a sensitivity of 1.00 (95% CI 0.87 to 1.00) and specificity of 0.40 (95% CI 0.25 to 0.56). Overall the CPSS was preferred in the prehospital setting and ROSIER used in the ED.

Chaudhary et al. (2022) found similar results from 29 included studies covering 11 screening tools. Fourteen studies on CPSS with overall sensitivity of 82.8% (95%CI 75.8-88.2) and specificity of 56.3% (95%CI 45.7 to 66.2). Only four studies were deemed to be lower risk of bias, and when these four studies were pooled the sensitivity and specificity of CPSS was 82.1% (95% CI 75.4 to 87.3) and 71.6% (95% CI 66.2% to 76.5). Seven studies using the FAST scale found overall sensitivity of 88.6% (95% CI 79 to 94.1) and specificity 55.5% (95% CI 31.7 to 76.9). Seven studies involved the LAPSS found overall sensitivity of 73.7% (95% CI 64.7 to 81.2) and specificity of 88.7% (95% CI 75.5 to 95.2). Four studies of the MASS found overall sensitivity of 85.5% (95% CI 82.5 to 88.2) and specificity of 74.6% (95% CI 61.5 to 84.4). Eleven studies of the ROSIER scale found overall sensitivity of 90.5% (95% CI 86.4 to 93.5) and specificity of 63.8% (95% CI 46.0 to 78.4). Three studies on the MedPACS found sensitivity ranging from 71% to 96% and specificity ranging from 33% to 92%. The sensitivity of the more common tools are similar but specificity is low. The performance of the tool could vary between settings (prehospital vs ED) and study type (prospective vs retrospective).

Han et al. (2020)[103] focused on accuracy of the ROSIER scale and included 14 studies (15 data sets). They found a pooled sensitivity of 0.88 (95% CI 0.83 to 0.91; 14 studies; substantial heterogeneity $I^2= 91\%$), specificity 0.66 (95% CI 0.52 to 0.77; 14 studies; substantial heterogeneity $I^2= 97\%$) and diagnostic OR 13.86 (95% CI 7.76 to 25.07; 14 studies; substantial heterogeneity $I^2= 100\%$).

De Luca et al (2019)[106] included 11 studies involving the CPSS in ED and found a sensitivity of 82.46% (95% confidence interval [CI] 74.83–88.09%) and specificity of 56.95% (95% CI 41.78–70.92).

Chen et al. (2021) [112] with 9 observational studies (n= 6,151) compared FAST and BEFAST for acute ischemic stroke. Of the three studies investigating BEFAST only one (Pickham et al 2019) was a prospective study in the pre-hospital setting which found no difference in accuracy compared to FAST (AUC 0.70 vs 0.69). Further studies are needed to determine the utility of the BEFAST scale over the simplified FAST scale.

Outcome Timeframe	Study results and measurements	Comparator Confirmed diagnosis	Intervention Stroke screening tool	Certainty of the Evidence (Quality of evidence)	Plain language summary
Identification of stroke or TIA using ROSIER 7 Critical	Based on data from 2,895 participants in 8 studies. ¹ (Observational (non- randomized))	The Recognition of Stroke in the Emergency Room (ROSIER; 8 studies [5 in ED setting], n= 2895) scale had a summary sensitivity of 0.88 (95% CI 0.84 to 0.91) and study level specificity range of 0.18 to 0.93. Two of the studies had high risk of bias or applicability concerns.		Moderate Due to serious risk of bias ²	The ROSIER scale has good sensitivity but lower specificity with high variation between studies.
Identification of stroke or TIA using the CPSS 7 Critical	Based on data from 4,157 participants in 11 studies. ³ (Observational (non- randomized))	The Cincinnati Prehospital Stroke Scale (CPSS; 11 studies, n= 4157, almost all prehospital setting) had a sensitivity range of 0.44 to 0.95 and specificity range of 0.21 to 0.79. Nine studies had high risk of bias or applicability concerns.		Low Due to serious risk of bias ⁴	The CPSS varies in sensitivity and specificity
Identification of stroke or TIA using the FAST 7 Critical	Based on data from 1,894 participants in 5 studies. ⁵ (Observational (non- randomized))	Face Arm Speech Time (FAST; five studies [3 prehospital and 2 in ED], n= 1894) had sensitivity of 0.64 to 0.97, specificity of 0.13 to 0.92 and 3 studies of high risk of bias or applicability concerns.		Low Due to serious risk of bias ⁶	The FAST varies in sensitivity and specificity
Identification of stroke or TIA using the LASPP 7 Critical	Based on data from 1,794 participants in 5 studies. ⁷ (Observational (non- randomized))	The Los Angeles Prehospital Stroke Scale (LAPSS; 5 five studies [all prehospital], n= 1794) had sensitivity of 0.83 (95% CI 0.75 to 0.89), specificity of 0.93 (95% CI 0.88 to 0.96) and 4 studies at high risk of bias or applicability concerns.		Low Due to serious risk of bias ⁸	The LASPP has good sensitivity and specificity

1. Systematic review [105].

2. **Risk of Bias: serious.** High risk of bias or applicability concern. **Inconsistency: no serious.** **Indirectness: no serious.** **Imprecision: no serious.** **Publication bias: no serious.**

3. Systematic review [105].

4. **Risk of Bias: serious.** High risk of bias or applicability concern. **Inconsistency: no serious.** **Indirectness: no serious.** **Imprecision: no serious.** **Publication bias: no serious.**

5. Systematic review [105].

6. **Risk of Bias: serious.** High risk of bias or applicability concern. **Inconsistency: no serious.** **Indirectness: no serious.** **Imprecision: no serious.** **Publication bias: no serious.**

7. Systematic review [105].

8. **Risk of Bias: serious.** High risk of bias or applicability concern. **Inconsistency: no serious.** **Indirectness: no serious.** **Imprecision: no serious.** **Publication bias: no serious.**

Attached Images

Info Box

Practice points

- Initial diagnosis should be reviewed by a clinician experienced in the evaluation of stroke.
- Stroke severity should be assessed and recorded on admission by a trained clinician using a validated tool (e.g. NIHSS).
- A blood glucose reading should be taken to improve specificity (hypoglycaemia can present as a 'stroke mimic').

Rationale

Early assessment by a 'stroke' clinician will provide continuity of care and the identification of patients suitable for stroke intervention. There is a potential risk that concentration of skill with the stroke team may lead to slower treatment if that team is not present (e.g. after hours), due to reduced familiarity of the emergency department staff with stroke assessment protocols.

Clinicians should use a validated tool to enable an appropriate response and timely treatment.

Early identification of a low blood sugar level can lead to blood glucose correction and detection of hypoglycaemia mimicking stroke.

Investigations

Once a clinical diagnosis of stroke has been made, additional investigations are used to confirm the diagnosis and to determine the cause of the event, specifically if it is cardiac or carotid in origin. Routine investigations should include full blood count, electrolytes, erythrocyte sedimentation rate, C-reactive protein, renal function, cholesterol and glucose levels, although direct evidence is lacking for each of these investigations. An ECG should also be conducted routinely to detect AF. If clinical history, imaging and routine investigations do not adequately identify the underlying cause then further investigations may be warranted.

Imaging

While stroke and TIA are clinical diagnoses, brain imaging is needed to confirm cerebral ischaemia or intracerebral haemorrhage (ICH) and exclude stroke mimics. To confirm the diagnosis and differentiate ICH from ischaemic stroke, MRI is widely considered the imaging modality of choice. However, the longer imaging time compared to CT and the limited availability of MRI scanners in many centres limit the routine application of MRI, and it is likely that CT will remain the most frequently used imaging modality for the foreseeable future. Advanced MRI and CT imaging techniques may be used to identify ischaemic and potentially viable brain tissue and thus guide intervention decisions in the hyperacute phase.

According to the most recent clinical audit of stroke services in Australia, 99% of stroke patients underwent brain scanning, among whom 79% had a CT scan, 3% had MRI, and 17% had both (Stroke Foundation 2012 [7]). The median time from arrival in ED to brain scan was 1:13 hours, and 38% of patients had the brain scan within an hour of arrival (Stroke Foundation 2012 [7]). In terms of vascular imaging, the scan of carotid arteries was performed in 62% of patients (Stroke Foundation 2012 [7]).

Brain imaging

Strong recommendation

All patients with suspected stroke who are candidates for reperfusion therapies should undergo brain imaging immediately. All other suspected stroke patients should have an urgent brain CT or MRI ('urgent' being immediately where facilities are available and preferably within 60 minutes). (Brazzelli et al. 2009 [41])

Practical Info

In the current Australian context CT is much more easily accessible than MRI and therefore facilitates faster initiation of reperfusion therapies.

Brain imaging is the "rate limiting step" in therapy decisions and should therefore be prioritised in the system of care. Ambulance pre-notification of suspected stroke patients and direct transport to the CT scanner on the ambulance stretcher is strongly encouraged.

Evidence To Decision

Benefits and harms

Substantial net benefits of the recommended alternative

Ischaemic stroke and intracerebral haemorrhage cannot be reliably differentiated on clinical grounds. Brain imaging with CT or MRI is therefore essential for accurate diagnosis and determination of management. Treatment is time-critical with benefit declining rapidly with passing minutes. Brain imaging should therefore occur immediately for patients who are potential candidates for reperfusion treatments. Rapid confirmation of the diagnosis of stroke facilitates direct access to stroke units, which improves outcomes for all stroke patients and the distinction between intracerebral haemorrhage and ischaemic stroke changes management (e.g. blood pressure and thromboprophylaxis), hence the recommendation that all stroke patients should have brain imaging within 60 minutes of arrival in hospital (see Stroke unit care and Acute blood pressure lowering therapy in [Acute medical and surgical management](#) chapter and Deep venous thrombosis in [Managing complications](#) chapter).

Although MRI is more sensitive than non-contrast CT for diagnosis of ischaemic stroke, it may not be immediately accessible, leading to treatment delays (Brazzelli et al. 2009 [41]). There are also some patients who cannot have MRI due to metallic implants and the cost is greater than CT.

Certainty of the Evidence

High

The evidence is based on observational studies but this is standard for studies of diagnostic accuracy.

Values and preferences

No substantial variability expected

In general CT brain imaging is preferred in the Australian setting due to accessibility.

Resources and other considerations

Important issues, or potential issues not investigated

Resources considerations

Earnshaw et al. (2012) [53] found MRI to be more effective and cost-saving than unenhanced CT selection of patients for thrombolysis, but MRI was less effective and more costly than CT perfusion imaging.

Implementation considerations

There is a clinical indicator collected in the National Stroke Audit on whether patients underwent brain imaging and, if so, what type. There are additional clinical indicators collected on the median time from arrival in the emergency department to the time of brain imaging and whether the patient was assessed for the administering of tPA. There are organisational indicators collected in the National Stroke Audit on whether hospitals have access to CT scanning within 1 hour of presentation to hospital for patients potentially eligible for thrombolysis and whether this access is available 24/7.

Rationale

Ischaemic stroke and intracerebral haemorrhage cannot be reliably differentiated on clinical grounds. Brain imaging with CT or MRI is therefore essential to accurate diagnosis and determination of management. Treatment is time-critical with benefit declining rapidly with passing minutes. Brain imaging should therefore occur immediately for patients who are potential candidates for reperfusion treatments. Rapid confirmation of the diagnosis of stroke facilitates direct access to stroke units which improves outcomes for all stroke patients and the distinction between intracerebral haemorrhage and ischaemic stroke changes management (e.g. blood pressure and thromboprophylaxis), hence the recommendation that all stroke patients should have brain imaging within 60 minutes of arrival in hospital (see Stroke unit care and Acute blood pressure lowering therapy in [Acute medical and surgical management](#) chapter and Deep venous thrombosis in [Managing complications](#) chapter).

Although MRI is more sensitive than non-contrast CT for diagnosis of ischaemic stroke (Brazzelli et al. 2009 [41]), it may not be immediately accessible leading to treatment delays. There are also some patients who cannot have MRI due to metallic implants and the cost is greater than CT.

Clinical Question/ PICO

Population: Adults with suspected stroke
Intervention: CT
Comparator: Confirmed diagnosis of stroke

Summary

A Cochrane review by Brazzelli et al. (2009)[41] reviewed computed tomography (CT) compared to magnetic resonance imaging (MRI) with eight studies and 308 participants. From seven studies and 226 patients with ischaemic stroke, CT within 12 hours of stroke onset had median sensitivity 45% (range 0.11 to 0.75) and median specificity 100%.

A review with studies from the HERMES collaboration by Román et al. (2018)[83] explored effectiveness of a baseline brain imaging tool (non contrast CT or MRI) to select acute ischaemic stroke patients with target artery occlusion and when there is a salvageable brain beyond occlusion for endovascular thrombectomy compared with standard medical therapy. Data was pooled from seven studies and 1764 patients. 1388 patients received a CT scan and 364 patients received a MRI scan as pre-randomisation brain imaging. Treatment with EVT reduced disability at 90 days (adjusted cOR 2.00, 95% CI 1.69 to 2.38) compared to standard treatment for a range of imaging features at baseline.

Choi et al. (2020) [84] completed a review exploring dual-energy CT (DECT) for differentiating acute intracranial haemorrhage (ICH) with nine studies and 402 patients. The overall pooled sensitivity and specificity of DECT for ICH

detection were 96% (95% CI 77 to 99%; substantial heterogeneity $I^2 = 90.3\%$) and 98% (95% CI 93 to 100%; moderate heterogeneity $I^2 = 57.9\%$). Studies including only stroke patients affected the heterogeneity with lower sensitivity (43.5% vs 94.2%) and higher specificity (98.7% vs 92.6%) than mixed aetiologies.

Outcome Timeframe	Study results and measurements	Comparator Confirmed diagnosis of stroke	Intervention CT	Certainty of the Evidence (Quality of evidence)	Plain language summary
Diagnosis of ischaemic stroke 7 Critical	Based on data from 226 participants in 7 studies. ¹ (Observational (non- randomized))	In Cochrane review, CT within 12 hours of stroke onset had median sensitivity 45% and median specificity 100%		High Although patient test population was largely lacking stroke mimics, Upgraded due to Large magnitude of effect ²	Non-contrast CT within 12 hours of stroke onset has moderate sensitivity and high specificity

1. Systematic review [41].
2. Inconsistency: no serious. Indirectness: no serious. Imprecision: no serious. Publication bias: no serious. Upgrade: large magnitude of effect.

Attached Images

Clinical Question/ PICO

Population: Adults with suspected stroke
Intervention: MRI
Comparator: Confirmed diagnosis of stroke

Summary

A Cochrane review by Brazzelli et al. (2009)[41] reviewed computed tomography (CT) compared to diffusion-weighted magnetic resonance imaging (MRI) with eight studies and 308 participants. From seven studies and 226 patients, MRI for diagnosis of ischaemic stroke had a pooled median estimate of sensitivity of 100% (range 0.73 to 1.00) and median specificity of 100% (range 0.86 to 1.00) in comparison to non-contrast CT which had a median sensitivity of 45% (range 0.11 to 0.75) and median specificity of 100%.

Outcome Timeframe	Study results and measurements	Comparator Confirmed diagnosis of stroke	Intervention MRI	Certainty of the Evidence (Quality of evidence)	Plain language summary
Diagnosis of ischaemic stroke	Based on data from 226 participants in 7 studies. ¹ (Observational (non- randomized))	In Cochrane review, MRI for diagnosis of ischaemic stroke had a pooled estimate of Sensitivity = 100% (median) and Specificity = 100% (median) in comparison to non-		High Although patient test population was largely lacking stroke	Diffusion MRI increases accuracy of diagnosis of ischaemic stroke compared with non- contrast CT

Outcome Timeframe	Study results and measurements	Comparator Confirmed diagnosis of stroke	Intervention MRI	Certainty of the Evidence (Quality of evidence)	Plain language summary
7 Critical		contrast CT which had a median sensitivity of 45% and median specificity of 100%.		mimics, Upgraded due to Very large magnitude of effect ²	

1. Systematic review [41].
2. **Inconsistency: no serious. Indirectness: no serious. Imprecision: no serious. Publication bias: no serious. Upgrade: very large magnitude of effect.**

Attached Images

Weak recommendation

In patients with suspected stroke and TIA, MRI is more sensitive and specific than non-contrast CT and is the preferred modality when diagnostic confirmation is required. (Brazzelli et al. 2009 [41])

Practical Info

Where MRI access is limited a "diffusion-only" protocol may allow the diagnostic benefit of MRI with a very rapid scan time.

The pattern of diffusion lesion may also provide clues to stroke aetiology, e.g. multiple vascular territory involvement may indicate a cardioembolic source. Some patients with resolved symptoms will have their diagnosis altered from TIA to stroke by the finding of a lesion on diffusion MRI, which places them in a higher risk category for stroke recurrence.

Evidence To Decision

Benefits and harms

Substantial net benefits of the recommended alternative

MRI is markedly more sensitive than non-contrast CT for diagnosis of ischaemic stroke (Brazzelli et al. 2009 [41]). Specificity and differentiation of stroke mimics are also better using MRI. This is particularly applicable to minor stroke patients, in whom non-contrast CT is often normal, and some patients with resolved symptoms will have their diagnosis altered from TIA to stroke by the finding of a lesion on diffusion MRI. Patients with diffusion lesions are at higher risk of stroke recurrence. A finding of multi-territory diffusion lesions can indicate pathogenesis (i.e. central embolic source). There are, however, some patients who cannot have MRI due to metallic implants and the cost is greater than CT.

Certainty of the Evidence

High

The evidence is based on observational studies but this is standard for studies of diagnostic accuracy.

Values and preferences

Substantial variability is expected or uncertain

If the patient is able to have MRI and resources are available then MRI would be preferred. However, MRI may not be available in all institutions, which may delay treatment with stroke reperfusion treatment.

Resources and other considerations

Important issues, or potential issues not investigated

Resources considerations

Economic evaluations comparing MRI and CT have been conducted for a European setting. Economic evaluations comparing MRI and CT have been conducted for a European setting. Earnshaw et al. 2012 [53] found MRI to be more effective and cost-saving than unenhanced CT selection of patients for thrombolysis, but MRI was dominated by CT perfusion imaging. Wardlaw et al. 2014 [19] found that MRI was not cost-effective (given a willingness to pay of £30,000 per QALY gained) compared to CT imaging for the routine diagnosis and management of TIA and minor stroke in a variety of scenarios tested. In a single centre study in Europe, it was found that MRI was cost-effective at an additional €11,869 per QALY gained compared to CT-based methods (cost reference year 2004) [62].

Rationale

MRI is substantially more sensitive for diagnosis of ischaemic stroke and may provide clues to stroke aetiology if multi-territory infarction is detected (Brazzelli et al. 2009 [41]). This is particularly applicable to minor stroke patients who may have a normal CT brain and patients with resolved symptoms who may have their diagnosis converted from TIA to stroke with an attendant increase in their estimated risk of stroke recurrence. However, MRI is not universally available and the frequency with which it changes management is uncertain.

Clinical Question/ PICO

Population: Adults with suspected stroke
Intervention: MRI
Comparator: Confirmed diagnosis of stroke

Summary

A Cochrane review by Brazzelli et al. (2009)[41] reviewed computed tomography (CT) compared to diffusion-weighted magnetic resonance imaging (MRI) with eight studies and 308 participants. From seven studies and 226 patients, MRI for diagnosis of ischaemic stroke had a pooled median estimate of sensitivity of 100% (range 0.73 to 1.00) and median specificity of 100% (range 0.86 to 1.00) in comparison to non-contrast CT which had a median sensitivity of 45% (range 0.11 to 0.75) and median specificity of 100%.

Outcome Timeframe	Study results and measurements	Comparator Confirmed diagnosis of stroke	Intervention MRI	Certainty of the Evidence (Quality of evidence)	Plain language summary
Diagnosis of ischaemic stroke 7 Critical	Based on data from 226 participants in 7 studies. ¹ (Observational (non- randomized))	In Cochrane review, MRI for diagnosis of ischaemic stroke had a pooled estimate of Sensitivity = 100% (median) and Specificity = 100% (median) in comparison to non- contrast CT which had a median sensitivity of 45% and median specificity of 100%.		High Although patient test population was largely lacking stroke mimics, Upgraded due to Very large magnitude of effect ²	Diffusion MRI increases accuracy of diagnosis of ischaemic stroke compared with non- contrast CT

1. Systematic review [41].
2. Inconsistency: no serious. Indirectness: no serious. Imprecision: no serious. Publication bias: no serious. Upgrade: very large magnitude of effect.

Attached Images

Good practice statement**Consensus-based recommendation**

Either CT or MRI are acceptable acute imaging options but these need to be immediately accessible to avoid delaying reperfusion therapies.

Rationale

MRI has advantages over CT in terms of diagnostic precision but safety checks for metallic implants, scanner access and patient contraindications and claustrophobia are currently practical limitations on the use of MRI in acute stroke. The randomised trials of reperfusion therapies predominantly used CT-based imaging. The fastest imaging approach that can deliver the necessary information should be used.

Strong recommendation

If using CT to identify hyperdense thrombus, thin slice (< 2 mm) non-contrast CT should be used rather than the standard 5 mm slices to improve diagnostic sensitivity for vessel occlusion. (Mair et al. 2015 [46])

Practical Info

CT scanners can reconstruct the single CT brain acquisition with varying slice thickness and in varying planes (i.e. without any added radiation or acquisition time). Thin slices (< 2 mm thickness) reduce partial voluming effects and make hyperdense thrombus within a vessel more conspicuous, achieving ~90% sensitivity for large vessel occlusion. These thin slices should not be used to assess grey-white differentiation (early ischaemic change) as they have increased image noise.

Evidence To Decision**Benefits and harms****Substantial net benefits of the recommended alternative**

Thin slice non-contrast CT is a re-format of the standard acquisition and therefore does not require any extra radiation or acquisition time. The benefit in sensitivity to vessel occlusion is marked (Mair et al. 2015 [46]).

Certainty of the Evidence**High**

The evidence is based on observational studies but this is standard for studies of diagnostic accuracy.

Values and preferences**No substantial variability expected**

No substantial variability is expected as thin slice non-contrast CT improves diagnostic accuracy with no extra cost.

Resources and other considerations**Factor not considered****Rationale**

Thin slice reconstructions of the non-contrast CT substantially improve diagnostic sensitivity for large vessel occlusion and do not come at any cost in terms of radiation or time.

Clinical Question/ PICO

Population:	Adults with suspected stroke
Intervention:	Thin slice non-contrast CT
Comparator:	Confirmed diagnosis of vessel occlusion

Summary

A review by Mair et al. (2015)[46] explored hyperdense artery sign on non-contrast computed tomography for the diagnosis of vessel occlusion with 17 studies and 1175 patients. It had 52% sensitivity (95% CI 41.2 to 63.4; 17 studies, n= 1175) and 95% specificity (95% CI 92.5 to 96.6; 13 studies, n=905). There was a significant association between CT slice-thickness and sensitivity of HAS ($r = -0.72$; $P = 0.002$), but no significant relationship for specificity. The one paper that used 1mm thin slices had 100% sensitivity with similar specificity. A study not included in the systematic review by Riedel et al. (2012)[56] had areas under the curve between 0.94 and 0.97 ($n = 158$).

Outcome Timeframe	Study results and measurements	Comparator Confirmed diagnosis of vessel occlusion	Intervention Thin slice CT	Certainty of the Evidence (Quality of evidence)	Plain language summary
Diagnosis of vessel occlusion 7 Critical	Based on data from 1,175 participants in 16 studies. ¹ (Observational (non-randomized))	In systematic review (Mair 2015), hyperdense artery sign had 52% sensitivity and 95% specificity. There was a significant association between CT slice-thickness and sensitivity of HAS ($r = -0.72$; $P = 0.002$), but no significant relationship for specificity. The one paper that used 1mm thin slices had 100% sensitivity with similar specificity. Another paper not included in the systematic review (Riedel 2012) had 94% sensitivity.		High	Thin slice (<2mm) non- contrast CT increases diagnostic sensitivity for vessel occlusion compared with 5mm slices.

1. Systematic review [46]. **Supporting references:** [56],

Attached Images

Weak recommendation

CT perfusion imaging may be used in addition to routine imaging to improve diagnostic and prognostic accuracy. (Biesbroek et al. 2012 [49])

Practical Info

CT perfusion imaging involves repeated imaging of the brain during the passage of an intravenous contrast bolus. Delayed blood flow arrival can indicate the presence of ischaemic stroke. Regions of severely reduced blood flow are likely to be irreversibly injured and large regions are associated with a worse prognosis. Despite the diagnostic and prognostic benefits of CT perfusion, studies to date have not shown modification of reperfusion treatment effect, i.e. patients still appear to benefit to some degree from reperfusion therapies delivered within standard time windows, despite quite large areas of irreversible injury. Whether patient selection based on CT perfusion may allow extension of the therapeutic time window for intervention is the subject of ongoing randomised trials.

Evidence To Decision

Benefits and harms

Substantial net benefits of the recommended alternative

CT perfusion is markedly more sensitive than non-contrast CT for diagnosis of ischaemic stroke, especially when using scanners capable of whole brain coverage (Biesbroek et al. 2012 [49]). CT perfusion is also more sensitive than CT

angiography in patients with small distal vessel occlusions (Biesbroek et al. 2012 [49]). There are, however, some patients with lacunar stroke or reperfused ischaemic stroke who are not detected using CT perfusion, for whom diffusion MRI can detect the lesion.

Certainty of the Evidence

High

The evidence is based on observational studies but this is standard for studies of diagnostic accuracy.

Values and preferences

Substantial variability is expected or uncertain

There is some extra contrast, radiation dose and time required to perform CT perfusion.

Resources and other considerations

No important issues with the recommended alternative

Resources considerations

CT perfusion imaging was more effective and cost-saving than usual CT-based methods for the selection of patients for thrombolysis (Jackson et al. 2010 [54]), and multimodal CT was also found to be more effective and cost saving over non-contrast CT (Young et al. 2010 [55]). Earnshaw et al. (2012) [53] found MRI to be dominant over unenhanced CT selection of patients for thrombolysis, but MRI was less effective and more costly than CT perfusion imaging.

Rationale

CT perfusion undoubtedly improves diagnostic and prognostic accuracy (Biesbroek et al. 2012 [49]). However, the extra time, contrast and radiation involved need to be balanced against the lack of definitive evidence that use of CT perfusion improves patient outcomes and hence the weaker recommendation.

Clinical Question/ PICO

- Population: Adults with suspected stroke
- Intervention: CT perfusion imaging
- Comparator: Confirmed diagnosis of stroke

Summary

A review by Biesbroek et al. (2013)[49] explored CT perfusion imaging with 15 observational studies and 1107 participants. The pooled sensitivity for CT perfusion was 80% (95% CI 72 to 86%) and specificity was 95% (95% CI 86 to 98%).

Katyal et al. (2021) [107] included 14 observational studies (n= 2074) and undertook meta-analysis on diagnostic accuracy in nine studies exploring CT perfusion imaging in posterior circulation acute ischemic stroke. Overall accuracy (area under the curve 0.90 vs 0.96) was similar, sensitivity was higher (72% vs 25%) and specificity slightly lower (90% vs 96%).

Outcome Timeframe	Study results and measurements	Comparator Confirmed diagnosis of stroke	Intervention CT Perfusion	Certainty of the Evidence (Quality of evidence)	Plain language summary
Diagnosis of ischaemic stroke	Based on data from 1,107 participants in 15 studies. ¹ (Observational	Systematic review and meta-analysis of 15 observational studies - CT perfusion sensitivity approximately		High	CT perfusion has greater sensitivity than non- contrast CT and CT angiography with high

Outcome Timeframe	Study results and measurements	Comparator Confirmed diagnosis of stroke	Intervention CT Perfusion	Certainty of the Evidence (Quality of evidence)	Plain language summary
	(non-randomized))	80% (95% CI: 72-86%), higher with whole brain coverage.			specificity

1. Systematic review [49].

Attached Images

Updated

Info Box

Practice points

- If a patient with stroke develops neurological deterioration, immediate clinical assessment and further brain imaging (CT or MRI) should be considered.
- Routine brain imaging approximately 24 hours after reperfusion therapies have been administered is recommended to identify haemorrhagic transformation and delineate the extent of infarction, both of which are important when making decisions about antithrombotic therapy and DVT prophylaxis.

Rationale

Changes in patient clinical status may reflect treatable or reversible pathology and should be rapidly investigated with brain imaging.

Repeating imaging routinely around 24 hours after reperfusion treatment is regarded as good practice to exclude significant haemorrhagic transformation that would alter subsequent antithrombotic management, as well as confirming the size of infarct which reflects the effectiveness of treatment and prognosis, and has implications for timing of anticoagulation in eligible patients.

Vascular imaging

Strong recommendation

- All patients who would potentially be candidates for endovascular thrombectomy should have vascular imaging from aortic arch to cerebral vertex (CTA or MRA) to establish the presence of vascular occlusion as a target for thrombectomy and to assess proximal vascular access. (Goyal et al. 2016 [52]; Broderick et al. 2013 [58])
- All other patients with carotid territory symptoms who would potentially be candidates for carotid re-vascularisation should have early vascular imaging to identify stenosis in the ipsilateral carotid artery. CT angiography (if not already performed as part of assessment for reperfusion therapies), Doppler ultrasound or contrast-enhanced MR angiography are all reasonable options depending on local experience and availability. (Netuka et al. 2016 [42]; Chappell et al. 2009 [43]; Nonent et al. 2011 [44]; Anzidei et al. 2012 [69])

Practical Info

Full cerebrovascular imaging of the aortic arch to cerebral vertex is strongly encouraged in all ischaemic stroke and TIA patients to facilitate accurate diagnosis of stroke aetiology and prognosis. Carotid imaging to determine eligibility for endarterectomy is a minimum requirement and should be performed as soon as possible using whichever modality is available locally. Aortic arch to vertex vascular imaging is essential for patients who are potential candidates for endovascular clot retrieval to confirm a target

for intervention and assess proximal vascular access. It is important to note that mild clinical severity does not exclude the presence of intra-cranial vessel occlusion. Approximately 10% of patients with minor stroke or even resolved symptoms have a major vessel occlusion and so mild clinical severity should not be used as an exclusion from vascular imaging with CTA or MRA. The presence or absence of vessel occlusion is a key determinant of risk of recurrent ischaemia or stroke progression. Patients with vessel occlusion are at substantial risk of subsequent clinical deterioration, whereas those without have a very low risk of stroke progression. Basilar artery occlusion is not always easy to differentiate from anterior circulation stroke on clinical grounds and hemiparesis is more common than tetraparesis. As the time window for intervention in basilar artery occlusion may be up to 24 hours at some centres, routine CT angiography would reduce the risk of missing the opportunity to treat this otherwise devastating condition.

Evidence To Decision

Benefits and harms

Substantial net benefits of the recommended alternative

Carotid imaging is critically important for people with carotid stenosis to identify candidates for endarterectomy which substantially reduces the risk of recurrent stroke in appropriate patients.

CT angiography (CTA) is highly accurate and shows the entire vascular tree, which has major advantages in accurately diagnosing stroke aetiology. CTA does involve ionising radiation and iodinated contrast, which may be associated with a low risk of contrast nephropathy in patients with severe pre-existing kidney disease. CTA is a routine part of initial brain imaging at many centres and is essential for patients who may be considered for endovascular thrombectomy. All randomised trials that demonstrated the benefits of endovascular thrombectomy used non-invasive vessel imaging (predominantly CTA) to assess eligibility (Goyal et al. 2016 [52]). The IMS-3 trial did not use CTA and was neutral overall but did demonstrate benefit in the subgroup of patients with demonstrated vessel occlusion (Broderick et al 2013 [58]).

If carotid imaging using CTA has not already been performed, Doppler ultrasound is widely available and requires no contrast or ionising radiation, but is operator dependent and visualises a relatively small region of the carotid circulation. Contrast-enhanced MR angiography is accurate but less widely available, and gadolinium contrast is contraindicated in kidney disease.

Certainty of the Evidence

Low

The evidence is based on observational data (standard for diagnostic accuracy studies).

Values and preferences

No substantial variability expected

No issues were identified.

Resources and other considerations

No important issues with the recommended alternative

Resources considerations

In economic evaluations duplex ultrasonography (US), computed tomographic (CT) angiography, contrast material-enhanced magnetic resonance (MR) angiography and a combination of these modalities have been compared for patients with TIA or minor ischaemic stroke suspected of having carotid artery stenosis.

There is evidence from two economic evaluations that ultrasound to identify patients requiring surgery for carotid stenosis was cost-effective per QALY gained (Buskens et al. 2004 [59]) and cost-effective per stroke prevented (Wardlaw et al. 2006 [60]) when compared to angiography. Adding MR angiography to ultrasound was not found to be cost-effective at an additional €1,500,000 per QALY gained compared to ultrasound alone (Buskens et al. 2004 [59]). In a cost-utility analysis, CT angiography with ultrasound was found to be cost-saving and more effective than intra-arterial angiography and ultrasound (Brown et al. 2008 [61]).

In another economic evaluation, it was found that US and CT angiography for people with 70–99% stenosis was a more effective and cost-saving strategy compared to other imaging modalities except when compared to the use of CT angiography for men with 70–99% stenosis, costing an additional €71,419 per QALY gained (reference year 2007) (Tholen et al. 2010 [76]).

Implementation considerations

There is a clinical indicator collected in the National Stroke Audit on whether patients underwent carotid imaging. There are also organisational indicators collected on whether hospitals have access to carotid imaging within 24 hours of admission and whether hospitals have access to, and use, non-invasive angiography.

Rationale

People with carotid artery stenosis (CAS) may require carotid endarterectomy and therefore the accuracy of measuring the stenosis is important for indication of the CEA procedure. In the comparison between CT angiography, digital subtraction angiography, Doppler ultrasonography and MR angiography, the strongest correlation coefficient and the best allocation of stenosis into clinical significant groups (<50%, 50–69%, ≥70%) was observed for CTA. Netuka concluded that CTA yielded the best accuracy in detection of carotid stenosis provided all axial slices of the stenosis are checked and carefully analysed (Netuka et al. 2016 [42]). In an individual patient data meta-analysis (Chappell et al. 2009 [43]) where ultrasonography, CTA, MR angiography and contrast material-enhanced MT angiography were compared to diagnose both severe and moderate symptomatic CAS, contrast-enhanced MR angiography was the most accurate for cases where stenosis was 70–99%. Benefits outweigh harms for both interventions and no issues were identified regarding values and preferences.

Clinical Question/ PICO

Population: Patients with carotid artery stenosis
Intervention: Imaging
Comparator: Surgical specimen

Summary

Netuka et al. (2016) [42] found that CTA underestimated histological measurement by 2.4% (based on European Carotid Surgery Trial [ECST] methodology) and 11.9% (based on North American Symptomatic Carotid Endarterectomy Trial [NASCET] methodology). Digital subtraction angiography (DSA) underestimated the histological measurement by 7% (ECST) and 12.2% (NASCET). MRA overestimated the histological measurement by 2.6% (ECST) and underestimated by 0.6% (NASCET). Doppler ultrasonography (DUS) overestimated the stenosis by 1.8%.

Cassola et al (2022) [114] conducted a Cochrane review of 22 studies (n = 4,957) on the accuracy on duplex ultrasound (DUS) imaging for diagnosing carotid artery stenosis in symptomatic patients, verified by either digital subtraction angiography (DSA), computed tomography angiography (CTA), or magnetic resonance angiography (MRA). DUS versus DSA accuracy was high: < 50% carotid artery stenosis (sensitivity = 0.63, 95% CI: 0.48 to 0.76, specificity = 0.99, 95% CI: 0.96 to 0.99); 50% to 99% range, (sensitivity = 0.97, 95% CI: 0.95 to 0.98, specificity = 0.70, 95% CI: 0.67 to 0.73); 70% to 99% range, (sensitivity = 0.85, 95% CI: 0.77 to 0.91, specificity = 0.98, 95% CI: 0.74 to 0.90); and for occlusion (sensitivity = 0.91, 95% CI: 0.81 to 0.97, specificity = 0.95, 95% CI: 0.76 to 0.99). DUS versus CTA accuracy was high for occlusion (sensitivity = 0.95, 95% CI: 0.80 to 0.99, specificity = 0.91, 95% CI: 0.09 to 0.99).

Outcome Timeframe	Study results and measurements	Comparator Surgical specimen	Intervention Imaging	Certainty of the Evidence (Quality of evidence)	Plain language summary
Accuracy of characterization of carotid stenosis	Based on data from 152 participants in 1 studies. ¹ (Observational (non- randomized))	Correlation coefficient with histological findings was highest for CTA (r = 0.7), followed by DSA (r = 0.6), and relatively weak for MRA and DUS (r = 0.4).		Low Due to serious imprecision and serious risk of bias ²	CTA may have the best accuracy in detecting carotid stenosis, followed by DSA and MRA.

1. Primary study **Supporting references:** [42],
2. **Risk of Bias: serious.** high risk of bias according to QUADAS-2: potential issues in selecting patients and blinding of assessors. **Inconsistency: no serious.** **Indirectness: no serious.** **Imprecision: serious.** Only data from one study, Low number of patients. **Publication bias: no serious.**

Attached Images

Clinical Question/ PICO

Population:	Patients suspected of having carotid artery stenosis
Intervention:	Ultrasound, CT and MR angiography
Comparator:	Digital subtraction angiography

Summary

Chappell et al. (2009) [43] included 9 studies (n=1,074) and found contrast-enhanced MRA was the most accurate (sensitivity 0.85, 95%CI 0.69 to 0.93; specificity 0.85, 95%CI 0.76 to 0.92) for high grade stenosis. Accuracy was lower in ipsilateral compared to contralateral artery. Individual patient data sets was lower than literature values.

A Cochrane review by Mattioni et al (2020)[79] assessed the accuracy of Transcranial Doppler (TCD) and transcranial colour Doppler (TCCD) for the detection of stenosis and occlusions. Nine prospective cohort and randomised clinical studies and 493 participants were included in the review. The pooled sensitivity and specificity for TCD and TCCD were 95% (95% CI 0.83 to 0.99; 9 studies, n= 493) and 95% (95% CI 0.90 to 0.98; 9 studies, n= 493), respectively. Meaning in a cohort of 1000 people and a disease prevalence of 42%, 21 cases will be missed (95% CI 4 to 71) and 29 cases will be false positives (95% CI 12 to 58).

A review by Rojoa et al (2020)[81] explored the accuracy of ultrasonography compared to digital subtraction, cerebral angiography or surgery in diagnosing internal carotid artery occlusion with 23 studies and 5675 arteries. The pooled sensitivity and specificity were 0.97 (95% CI 0.94 to 0.99) and 0.99 (95% CI 0.98 to 1.00), respectively.

Forjoe et al (2019)[80] completed a review for preoperative carotid duplex ultrasound (CDU) compared to computed tomography angiography (CTA) with 45 mixed method studies. The sensitivity and specificity of CTA are 90.6% (9 studies, n= 1245) and 93% (9 studies, n= 1245), respectively. For CDU, the sensitivity and specificity were 92.3% (4 studies, n= 857) and 89% (4 studies, n= 857), respectively.

Outcome Timeframe	Study results and measurements	Comparator Digital subtraction angiography	Intervention Ultrasound, CT and MR angiography	Certainty of the Evidence (Quality of evidence)	Plain language summary
Accuracy of characterization	Based on data from 1,074 participants in 9	Individual patient data meta-analysis found contrast-enhanced MR		Moderate Due to serious	CE-MR probably has the best diagnostic accuracy

Outcome Timeframe	Study results and measurements	Comparator Digital subtraction angiography	Intervention Ultrasound, CT and MR angiography	Certainty of the Evidence (Quality of evidence)	Plain language summary
of carotid stenosis	studies. (Observational (non-randomized))	angiography was the most accurate (sensitivity, 0.85 [30 of 35]; 95% confidence interval [CI]: 0.69, 0.93; and specificity, 0.85 [67 of 78]; 95% CI: 0.76, 0.92) for 70%–99% symptomatic stenosis. Sensitivity for a 50%–69% stenosis was poor, although data were limited.		risk of bias ¹	for 70%-99% symptomatic stenosis

1. **Risk of Bias: serious.** Inadequate reporting for selection of patients and blinding of assessors according to QUADAS-2. **Inconsistency: no serious. Indirectness: no serious. Imprecision: no serious. Publication bias: no serious.**

Attached Images

Info Box

Practice points

- In ischaemic stroke and TIA patients, routinely imaging the entire vasculature from aortic arch to cerebral vertex with CTA or MRA is encouraged to improve diagnosis, recognition of stroke aetiology and assessment of prognosis.
- The administration of intravenous iodinated contrast for CT angiography/perfusion, when clinically indicated, should not be delayed by concerns regarding renal function. Post-hydration with intravenous 0.9% saline is advisable. (RANZCR guidelines 2016 [64]; Ang et al. 2015 [63]).

Rationale

Vascular imaging in ischaemic stroke and TIA patients can guide management beyond simply identifying carotid stenosis requiring endarterectomy. Other vessel pathologies (e.g. dissection) and pathology at sites other than the carotid bifurcation (e.g. aortic arch atheroma, vertebrobasilar disease, intracranial stenosis) can be identified if the complete vascular network is imaged. Patients with high grade stenosis or occlusion are at substantially higher risk of recurrent ischaemia.

Info Box

Practice point

Vascular imaging should not be performed for syncope or other non-focal neurological presentations.

Cardiac investigations

Echocardiography is an important tool in the detection of cardiac source of embolism. In patients where the stroke mechanism is uncertain after relevant intracranial or extra-cranial imaging, transthoracic echocardiography (TTE) should be considered. The timing and urgency of the test depends on the level of suspicion of cardioembolic source. Both TTE and trans-oesophageal echocardiography (TOE) have advantages and disadvantages and the use of TOE after a normal TTE should be individualised.

Atrial fibrillation (AF) is detected with electrocardiography (ECG). The optimal duration and device for ECG monitoring remain to be determined. ECG monitoring is also used in the early phase of stroke to identify cardiac complications including arrhythmia.

Weak recommendation

Initial ECG monitoring should be undertaken for all patients with stroke. The duration and mode of monitoring should be guided by individual patient factors but would generally be recommended for at least the first 24 hours. (Kurka et al. 2015 [66])

Evidence To Decision**Benefits and harms**

Small net benefit, or little difference between alternatives

The early phase after stroke can be associated with cardiac complications including arrhythmia, and cardiac monitoring is advised in the initial period. This may also diagnose unrecognised paroxysmal atrial fibrillation relevant to stroke aetiology.

Certainty of the Evidence

Moderate

This recommendation is based on observational data but that is acceptable for diagnostic studies.

Values and preferences

Substantial variability is expected or uncertain

ECG monitoring is non-invasive and well tolerated, although not universally available in stroke units.

Resources and other considerations

Important issues, or potential issues not investigated

Resources considerations

No literature to understand or describe the potential economic implications of this recommendation was identified.

Rationale

Only one study examined the utility of telemetric monitoring in acute stroke patients prospectively. In this study, the automated detection missed no events (including atrial fibrillation) but the overall rate of false alarm was 27.4%. If one considers Holter monitoring as "continuous monitoring" then more studies are available. There is evidence to suggest that Holter monitoring, telemetric monitoring and standard ECGs are complementary methods in detecting atrial fibrillation in the acute stroke setting and no particular method is superior (Kurka et al 2015 [66]; Lazzaro et al. 2012 [72]; Douen et al. 2008 [73]; Gunalp et al. 2006 [74]).

Clinical Question/ PICO

Population: Adults with acute stroke
Intervention: Continuous ECG monitoring
Comparator: Standard ECG

Summary

There is very limited literature comparing ECG vs continuous monitoring in detection of atrial fibrillation (AF) in acute stroke patients if one considers continuous monitoring as telemetric monitoring only (excluding Holter monitoring). In the single study available (Kurka et al. 2015 [66]), 151 patients were included, 73.5% had ischaemic stroke, 18.5% had TIA and 8% had cerebral haemorrhage. A total of 4809.5 monitoring hours were elevated. 35 patients had known AF prior to admission, 6 had AF detected on admission ECG and 10 had AF detected during continuous monitoring.

When Holter monitoring is considered as well there is more literature available, but the evidence for the superiority of any particular monitoring method is limited. An observational study by Lazzaro et al. (2012) [72] assessed outcomes for 133 stroke and TIA patients registered prospectively in a stroke registry who received both Holter and continuous cardiac telemetry monitoring. Holter monitoring detected significantly more atrial fibrillation (6% vs 0%). However, the small size was small, with a small number of atrial fibrillation cases. In contrast, Douen et al. (2008) [73] studied 144 patients with ischaemic stroke. Atrial fibrillation was detected in 15 patients by serial ECG, but out of the 12 AF cases

who also had Holter monitoring, Holter monitoring only identified 6 (50%), suggesting Holter may underestimate atrial fibrillation. Gunalp et al. (2006) [74] had previously found Holter monitoring to be superior to serial ECG for detection of arrhythmias in an observational study of 26 patients with thromboembolic stroke and sinus rhythm. On the basis of these mixed results, there is no clear evidence for the superiority of any particular monitoring method.

Haeusler et al. 2021 [109] (n= 3,465) explored usual care with additional Holter-ECG recording for up to 7 days in hospital. At 12 months, 13.7% (203/1484) of the intervention and 11.8% (169/1436) of the control group were on oral anticoagulants (OR 1.2, 95% CI 0.9 to 1.5). AF was detected in 5.8% (97/1714) of the intervention and 4.0% (68/1717) of the control group (HR 1.4, 95% CI 1.0 to 2.0). Within 12 months after the index stroke, 9.7% patients in the intervention group and 8.1% patients in the control group were diagnosed with atrial fibrillation (OR 1.2, 95% CI 0.9 to 1.6). The composite outcome of cardiovascular outcomes and death did not differ between groups at 24 months (13.5% vs 14.5%; HR 0.9, 95% CI 0.8 to 1.1). All-cause death occurred in 4.3% of patients in the intervention group and 6.0% of the control group (OR 0.7, 95% CI 0.5 to 0.9). Skin reactions due to study ECG electrodes were reported in 3.3% of the intervention group.

Huang et al. 2021 [108] (n=826) explored 12-lead electrocardiograms once daily for 5 days compared with conventional 24hr Holter monitoring. There were similar rate of AF detection between serial ECGs and 24 hr Holter (8.4% vs 6.9%, aOR 1.17, 95% CI 0.69 to 2.01). Of the patients who had newly detected AF, 37.1% of those in the serial ECG group and 39.3% of those in the 24hr Holter group were on an oral anticoagulant on discharge, while at three months it was 51.4% of the serial ECG group and 64.3% of the 24hr Holter group.

Munro et al. (2018) [93] explored 12-lead electrocardiograms with 18 studies. No meta-analysis was conducted due to heterogeneity of studies, but the prevalence of AF was determined (15%; 7 studies, n= 1645). AF was associated with 3 month mortality in ischemic stroke patients (OR 2.0, 95% CI 1.3 to 3.1; 1 study, n= 692). Mortality was associated with presence of a Q wave in two or more leads (HR 3.42, 95% CI 1.43 to 8.19; 1 study, n= 216).

Outcome Timeframe	Study results and measurements	Comparator Standard ECG	Intervention Continuous ECG monitoring	Certainty of the Evidence (Quality of evidence)	Plain language summary
Detection of atrial fibrillation 7 Critical	Based on data from 151 participants in 1 studies. ¹ (Observational (non- randomized)) Follow up: about 30 hours per patient.	Only one study specifically reported the rate of AF detection on admission ECG vs telemetric monitoring		Moderate Due to serious imprecision ²	Continuous ECG monitoring using automated arrhythmia detection is highly sensitive in acute stroke but has a high rate of false alarm

1. Primary study **Supporting references:** [66],
2. **Inconsistency: no serious. Indirectness: no serious. Imprecision: serious.** Only data from one study. **Publication bias: no serious.**

Attached Images

Strong recommendation

For patients with embolic stroke of uncertain source, longer term ECG monitoring (external or implantable) should be used. (Afzal et al. 2015 [67])

Practical Info

Embolic stroke of uncertain source (ESUS) is a relatively recently defined subgroup of what has previously been called "cryptogenic stroke". It aims to define a group at higher risk of occult paroxysmal atrial fibrillation and comprises a non-lacunar infarct in the absence of significant proximal vessel disease, a normal echocardiogram and at least 24 hours of unremarkable ECG monitoring.

Investigation for occult atrial fibrillation has traditionally involved one or more periods of Holter monitoring, although the evidence clearly shows this is insensitive. External loop recorders can be worn for up to 30 days subject to patient tolerance of the device. Implantable loop recorders can provide up to 3 years of continuous monitoring and simulations indicate that 30-day monitoring or repeated Holter monitoring would detect AF in only a minority of patients otherwise detected using implantable recorders. However, the cost is substantial and may not be reimbursed. Whilst there is some question about the relevance of AF detected many months after the stroke to its aetiology, late-detected AF remains a significant risk factor for subsequent stroke and, in the trials of extended duration monitoring, led to the commencement of anticoagulation in the majority of patients in whom AF was detected.

Evidence To Decision

Benefits and harms

Substantial net benefits of the recommended alternative

The detection of unrecognised paroxysmal atrial fibrillation is critically important to reduce the risk of recurrent stroke as antiplatelet agents are not effective and anticoagulation is required (see section Antiplatelet in chapter Secondary Prevention). Longer durations of monitoring are associated with increased AF detection. Twenty-four-hour Holter monitoring has been commonly used, but randomised controlled trials have demonstrated a substantial proportion of patients with paroxysmal AF were not detected using this approach (Afzal et al. 2015 [67]; Kamel et al. 2013 [71]). External loop recorder devices can be worn up to 30 days, but simulations based on implantable loop recorders indicate that a substantial proportion of AF was detected beyond the first 30 days. Device availability and reimbursement may be limiting factors. Safety of implantable loop recorders is acceptable, with very few adverse events reported.

Certainty of the Evidence

Moderate

Multiple randomised controlled trials reporting consistent results, with some potential risk of bias.

Values and preferences

Substantial variability is expected or uncertain

The availability and reimbursement for extended cardiac monitoring are variable and may limit implementation. A minor procedure (skin incision) is required for loop recorder implantation. Wearable devices are associated with a degree of discomfort and patient adherence may be an issue.

Resources and other considerations

No important issues with the recommended alternative

Resources considerations

There is evidence from an economic evaluation by Mayer et al. (2013) [75] that 7-day Holter monitoring is highly cost effective for detecting paroxysmal atrial fibrillation in patients with ischaemic stroke in comparison to 24-hour Holter monitoring [71]. In the least effective scenario tested in sensitivity analysis, 7-day Holter monitoring cost an additional €8,354 per QALY gained compared to 24-hour Holter monitoring when looking at benefits over a lifetime (cost reference year 2011).

Rationale

There is clear evidence that a longer duration of monitoring is associated with higher frequency of atrial fibrillation (AF) detection in patients with embolic stroke of uncertain source (Afzal et al. 2015 [67]; Kamel et al. 2013 [71]). When AF is detected and anticoagulation is commenced, the benefits for stroke prevention are well-established (see section Anticoagulant therapy in the Secondary Prevention chapter). Whether external or implantable monitors are used will depend on local availability and resources. Simulations based on implantable loop recorder data indicate that the majority of detected atrial fibrillation occurs beyond the first 30 days (the current maximum duration of external loop recording).

Clinical Question/ PICO

Population:	Adults with stroke
Intervention:	Long term ECG monitoring
Comparator:	Short term ECG monitoring

Summary

To date, there are three high-quality randomised controlled trials investigating the detection of atrial fibrillation with long term ECG monitoring. A meta-analysis by Afzal et al. pooled data and reported OR of 4.54 (95%CI 2.92–7.06) of detecting atrial fibrillation with long-term monitoring compared to routine outpatient follow-up (Afzal et al. 2015- [67]). The three randomised controlled trials reported in the systematic review used different technologies with varying duration of monitoring (7–180 days) and definition of atrial fibrillation (20 seconds to greater than 30 seconds) when compared to "routine practice" which is mostly 24-hr Holter monitoring (Afzal et al. 2015- [67]). A small pilot trial did not find any atrial fibrillation in 21 days of telemetry monitoring or outpatient follow-up and the authors believed it was due to low compliance – patients wore monitors for only 64% of assigned days (Kamel et al. 2013- [71]). Afzal et al. (2015) also pooled data from 13 observational studies and found that implantable loop recorders (ILR) detected more atrial fibrillation than wearable devices (23.3% compared to 13.6%) [67].

A review by Korompoki et al. (2017) [94] investigated cardiac monitoring for AF after TIA with 17 prospective observational studies and 1,163 patients. AF detection rates from all methods was 4% (95% CI 2 to 7; 17 studies, n= 1,163; moderate heterogeneity $I^2 = 60.61\%$) and rates rose with duration of monitoring (24 hrs: 4%, 95% CI 1 to 8; 24 hrs to 7 days: 5%, 95% CI 2 to 9; >7 days: 6%, 95% CI 1 to 12; 8 studies, n= 830) and the use of invasive monitoring compared to non invasive monitoring (11%, 95% CI 2 to 24; 15 studies vs 4%, 95% CI 2 to 7; 3 studies respectively; moderate heterogeneity $I^2 = 60.61\%$).

Dahal et al. (2016) [90] explored prolonged (>7 days) monitoring in cryptogenic stroke or TIA and identified four studies and 1,149 participants. Increased rate of AF detection of duration ≥ 30 seconds was found in prolonged monitoring compared to shorter (≤ 48 hour) cardiac monitoring (13.8% vs 2.5% respectively; OR 6.4, 95% CI 3.50 to 11.73; 3 studies, n= 1,039). Prolonged cardiac monitoring also increased the detection of any duration of AF when compared to shorter monitoring (22.6% vs 5.3 % respectively; OR 5.68, 95% CI 3.3 to 9.77; 3 studies, n= 701). Subsequent studies are consistent with the Dahal et al review. W achter et al. (2017) [97] investigated 10-day Holter-ECG monitoring compared to standard 24hr rhythm monitoring (n=398). AF was detected in 14% (27/200) of those who completed prolonged monitoring and 5% in the control group (9/198) with an absolute difference of 9% (95% CI 3.4 to 14.5). Kaura et al. (2019) [99] detected AF at 90 days in 16.3% (7/43) of patch-based monitoring group compared to 2.1% (1/47) in the short-duration ECG monitoring group (OR 8.9, 95% CI 1.1 to 76.0). Kulach et al. (2020) [102] reported 4 (5.6%) AF cases from 72 hour Holter monitoring, 7 (10%) cases from 7 day Holter. Gomis et al. (2019) [100] compared Holter-enabled continuous ECG monitoring in combination with Stroke Risk Analysis (hSRA) with standard continuous ECG monitoring for AF detection. From 524 patients, 45 cases of AF (9.7%) were confirmed. Continuous ECG monitoring detected 21 AF cases (4.3%) and (hSRA) detected high risk of AF patterns in 92 patients, 35 of them showed an episode of AF during Stroke Unit stay. The predictive values of hSRA were: sensitivity 71%, specificity 86%, positive predictive value 38% and negative predictive value 96%. Ross et al. (2018) [98] found the sensitivity of SRA compared to standard diagnostic in AF patients was 98% (95% CI 95.19 to 99.04), specificity 27% (95% CI 22.00 to 32.17), positive predictive value 56% (95% CI 51.71 to 60.45) and the negative predictive value of 92% (95% CI 84.63 to 96.82).

Specifically related to implantable loop recorders (ILR) Ko et al. 2021 [110] included three RCTs (n=1,233) and found ILR were more likely to detect AF compared to usual care (OR 5.8, 95% CI 3.2 to 10.2; 3 studies, n= 1,233; high quality of evidence). Stroke or TIA occurred in 7% of the ILR and 9% of usual care (OR 0.8, 95% CI 0.5 to 1.2; 3 studies, n= 1,233; moderate quality of evidence). Similarly, Tan et al. 2022 [111] with same three studies (n= 1,233) found the detection of AF was higher in the ILR group than the control group at 6 months (RR 4.63, 95% CI 2.17 to 9.90; 3 studies, n= 1,233) and 12 months (RR 5.04, 95% CI 2.93 to 8.68; 3 studies, n= 1,233). The ILR group had a higher rate of oral anticoagulant usage after the detection of AF (RR 2.76, 95% CI 1.89 to 4.02; 3 studies, n= 1,233). However, there was no difference between groups in the time to first detection of AF within 12 months (MD -8.28, 95% CI -77.84 to 61.28; 2 studies, n= 933), or the rate of recurrent ischaemic stroke or TIA (RR 0.88, 95% CI 0.60 to 1.28). The ILR groups experienced more adverse events than the control group within 12 months (RR 4.42, 95% CI 1.69 to 11.55; 3 studies, n= 1,233).

This is consistent to older, mainly non-randomised studies. Edwards et al. (2020) [91] investigated the implantable monitors and included one randomised control trial (n=441) and twenty-six observational studies (n=3414). By 36 months for the RCT, AF was detected in 19% of patients with an implantable cardiac monitor and in 2.3% of patients receiving conventional care. Tsivgoulis et al. (2019) [92] explored implantable cardiac monitoring with 28 studies (n=4531 ischemic stroke patients). The cumulative AF detection rate by implantable cardiac monitoring was 26% (95% CI 22% to 30%; 28 studies, n= 4531; moderate heterogeneity $I^2 = 83\%$).

An Australian observational study by Yan et al. (2020) [95] investigated smartphone-enabled handheld ECG (iECG) and 24-hour Holter monitoring for AF detection with 1,079 patients. AF was reported in 8.5% (25/294) by iECG compared to 2.8% (8/294) by 24-hour Holter recordings. AF was also detected in 8.8% (69/785) of those who underwent iECG only. A similar study (n=203) in the form of RCT was completed in Malaysia and detected AF lasting ≥ 30 seconds in 10 of 105 (9.5%) patients using a 30-day smartphone ECG recording compared to 2 of 98 (2%) patients who underwent an additional 24hr Holter monitoring (Koh et al., 2021 [96]).

Outcome Timeframe	Study results and measurements	Comparator Short term ECG monitoring	Intervention Long term ECG monitoring	Certainty of the Evidence (Quality of evidence)	Plain language summary
Detection of atrial fibrillation 7 Critical	Odds ratio 6.4 (CI 95% 3.5 – 11.73) Based on data from 1,039 participants in 3 studies. ¹ (Randomized controlled)		CI 95%	Moderate Due to serious risk of bias ²	Long term ECG monitoring probably improves detection of atrial fibrillation

1. Systematic review [90] . **Baseline/comparator:** Control arm of reference used for intervention.
2. **Risk of Bias: serious.** Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Inconsistency: no serious. Indirectness: no serious. Imprecision: no serious. Publication bias: no serious.**

Attached Images

Weak recommendation

Further cardiac investigations should be performed where clarification of stroke aetiology is required after initial investigations. In patients with ischaemic stroke, echocardiography should be considered based on individual patient factors. Transoesophageal echocardiography is more sensitive for suspected valvular, left atrial and aortic arch pathology. (Holmes et al. 2014 [68])

Evidence To Decision

Benefits and harms

Substantial net benefits of the recommended alternative

Echocardiography identifies more potential cardiac risk factors for strokes. Findings range from major risk factors such as severe valvular disease to minor risk factors such as patent foramen ovale (Holmes et al. 2014 [68]).

Certainty of the Evidence

Low

Diagnostic studies with some potential risk of bias and a wide range of performances in detecting different conditions.

Values and preferences

No substantial variability expected

None expected.

Resources and other considerations

Important issues, or potential issues not investigated

Resources considerations

Routine cardiac imaging using echocardiography was not cost-effective (given a willingness to pay of US\$50,000 per QALY gained) for identifying and treating intracardiac thrombus in patients with stroke or TIA (Meenan et al. 2007 [77]). Economic evaluations of cardiac investigations used to identify other stroke mechanisms are required.

Rationale

Echocardiography identifies more potential cardiac risk factors for strokes. Holmes et al. (2014) performed a systematic review comparing diagnostic performance of transthoracic echocardiography (TTE) and transoesophageal echocardiography (TOE) in the identification of cardiac source of stroke and TIA (excluding AF). Patent foramen ovale (PFO), atrial septal aneurysm and

mitral valve prolapse were the most commonly detected cardiac risk factors. In most cases, TTE and TOE have similar specificity and TTE had lower sensitivity. The reported sensitivity ranges widely and therefore one cannot be certain how many patients may be missed due to a low sensitivity (Holmes et al. 2014 [68]).

Clinical Question/ PICO

Population: Adults with cardiac conditions as potential sources of stroke or TIA
Intervention: Echocardiography
Comparator: Reference standard

Summary

A review compared CT angiography (CTA) and echocardiography for the detection of cardiac thrombi in ischemic stroke included fourteen single centre cohort studies and 1568 patients (Groeneveld et al. 2020 [78]). CTA detected cardiac thrombi in 6.3% (87/1385) of patients compared to 4.9% (68/1385) using transeophageal echocardiography (TEE) ($p < 0.001$; 10 studies, $n = 1385$). When compared to transthoracic echocardiography (TTE), CTA detected cardiac thrombi in 12.5% (23/183) of patients compared to 6.6% (12/183) on TTE ($p = 0.010$; 4 studies, $n = 183$). The pooled sensitivity and specificity of CTA compared to TEE were 86.0% (95% CI 65.6 to 95.2) and 97.4% (95% CI 95.0 to 98.7), respectively. When comparing CTA and TTE for any artery, the pooled sensitivity and specificity were 37.0% (95% CI 12.6 to 70.4) and 83.9% (95% CI 63.4 to 94.0), respectively.

A review by Katsanos et al (2016) [89] compared the use of transthoracic echocardiography (TTE), transcranial doppler (TCD), or both with transesophageal echocardiography (TEE) for the detection of PFO. Thirty-five observational studies and 3,067 patients were included. The pooled sensitivity and specificity for TCD was 96.1% (95% CI 93.0 to 97.8; 26 studies, $n = 1,815$) and 92.4% (95% CI 85.5 to 96.1; 26 studies, $n = 1,815$) and for TTE was 45.1% (95% CI 30.8 to 60.3%; 11 studies, $n = 1,258$) and 99.6% (95% CI 96.5 to 99.9; 11 studies, $n = 1,258$).

A study by Katsanos et al (2016) [85] investigated transesophageal echocardiography (TEE). From the prospective cohort of 1,134 ischemic stroke patients, 61 patients with embolic strokes of undetermined sources underwent TEE examination. Abnormal finding were found in 52% (95% CI 40 to 60%) and the TEE findings affected therapeutic management in 16% ($n = 10$, 95% CI 9 to 28%).

Holmes et al. (2014) [68] performed a systematic review comparing diagnostic performance of transthoracic echocardiography (TTE) and transoesophageal echocardiography (TOE) in the identification of the cardiac source of stroke and TIA (excluding atrial fibrillation). Patent foramen ovale (PFO), atrial septal aneurysm and mitral valve prolapse were the most commonly detected cardiac risk factors. In most cases, TTE and TOE have similar specificity and TTE had lower sensitivity. The reported sensitivity varies widely and therefore one cannot be certain how many patients may be missed due to a low sensitivity. Detection of PFO with TTE, for example, has a sensitivity ranging from 0 to 94% when compared with TOE, with a pooled point estimate of 34%.

Tanaka et al. (2014) [70] evaluated the association between the volume of the left atrial appendage measured by real-time three-dimensional TOE and presence of paroxysmal atrial fibrillation. The optimal cut-off for left atrial appendage peak flow velocity was 39.0 cm/s (sensitivity, 54.6%; specificity, 89.7%). This may be a promising method for detecting atrial fibrillation, but more studies will be needed to validate its diagnostic performance.

Outcome Timeframe	Study results and measurements	Comparator Reference standard	Intervention Echocardiography	Certainty of the Evidence (Quality of evidence)	Plain language summary
Detection of cardiac source of stroke 7 Critical	Based on data from participants in 51 studies. (Observational (non-randomized))	Based on a meta-analysis of diagnostic studies comparing TTE and TOE, TTE has high specificity of mostly 100% across various cardiac conditions but sensitivity ranging from 0 to 100%.		Low Due to serious risk of bias, Due to serious inconsistency ¹	TOE and TTE have comparable performance in specificity, but TTE may have a much lower sensitivity in detecting cardiac source of stroke.

1. **Risk of Bias: serious.** Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Inconsistency: serious.** Sensitivity for different conditions ranges from 0 to 0.99.

Attached Images

Glossary and abbreviations

Glossary

Activities of daily living: The basic elements of personal care such as eating, washing and showering, grooming, walking, standing up from a chair and using the toilet.

Activity: The execution of a task or action by an individual. Activity limitations are difficulties an individual may have in executing activities.

Agnosia: The inability to recognise sounds, smells, objects or body parts (other people's or one's own) despite having no primary sensory deficits.

Aphasia: Impairment of language, affecting the production or comprehension of speech and the ability to read and write.

Apraxia: Impaired planning and sequencing of movement that is not due to weakness, incoordination or sensory loss.

Apraxia of speech: Inability to produce clear speech due to impaired planning and sequencing of movement in the muscles used for speech.

Atrial fibrillation: Rapid, irregular beating of the heart.

Augmentative and alternative communication: Non-verbal communication, e.g. through gestures or by using computerised devices.

Central register: collection of large dataset related to patients' diagnoses, treatments and outcomes

Cochrane: Cochrane is a worldwide, not-for-profit organisation that produces systematic reviews of medical research. Systematic reviews summarise all the research that has been done on a given topic, so that health professionals, patients and policy-makers can make evidence-based decisions.

Cochrane are partnering with the Stroke Foundation on the Living Stroke Guidelines project.

Cochrane review: a comprehensive systematic review and meta-analysis published online in Cochrane library, internationally recognized as the highest standard in evidence-based health care resources

Conflict of Interest (COI) form: A conflict of interest form is signed by all working group members (including all members of the consumer panel). It highlights whether there is any risk of the person's professional judgement (eg. their assessment of research) being influenced by a secondary interest they may have, such as financial gain or career advancement.

Covidence: Covidence is computer software that Cochrane uses to help identify research for systematic reviews. It reduces the workload by allowing the person using it to quickly scan-read and screen scientific papers for relevance, make a summary of their main findings, and assess how well the research was done and whether there is a risk of bias.

Covidence will be used to screen all stroke-related research articles so that only the most accurate ones go into the Living Stroke Guidelines.

Deep vein thrombosis: Thrombosis (a clot of blood) in the deep veins of the leg, arm, or abdomen.

Disability: A defect in performing a normal activity or action (e.g. inability to dress or walk).

Drip and ship: A model of thrombolysis service provision that involves assessment of patients at a non-specialist centres with telemedicine support by stroke specialists, commencing thrombolysis (if deemed appropriate) and subsequent transfer to the stroke specialist centre.

Dyad: involvement of both patients and their caregivers

Dysarthria: Impaired ability to produce clear speech due to the impaired function of the speech muscles.

Dysphagia: Difficulty swallowing.

Dysphasia: Reduced ability to communicate using language (spoken, written or gesture).

Emotionalism: An increase in emotional behaviour—usually crying, but sometimes laughing that is outside normal control and may be unpredictable as a result of the stroke.

Endovascular thrombectomy (also called mechanical thrombectomy or endovascular clot retrieval): a minimally invasive procedure performed via angiogram, in which a catheter passes up into the brain to remove the clot in the blocked blood vessel.

Enteral tube feeding: Delivery of nutrients directly into the intestine via a tube.

Evaluation (of project): An evaluation is an assessment of a project. The aim of an evaluation is to determine the project's effectiveness, efficiency, impact and sustainability.

Evidence-based decision-making: Evidence-based decision-making is a process for making decisions about an intervention, practice etc, that is grounded in the best available research evidence.

Evidence summary: An evidence summary is a short summary of the best available evidence for a particular (guidelines') question. It aims to help clinicians use the best available evidence in their decision-making about particular interventions.

Executive function: Cognitive functions usually associated with the frontal lobes including planning, reasoning, time perception, complex goal-directed behaviour, decision making and working memory.

Family support / liaison worker: A person who assists stroke survivors and their families to achieve improved quality of life by providing psychosocial support, information and referrals to other stroke service providers.

GRADE: The GRADE approach (Grading of Recommendations Assessment, Development and Evaluation) is a standardised way of assessing research (also known as the *quality of evidence*) and determining the strength of recommendations. It was designed to be transparent and rigorous and has become the leading method used for guideline development.

GRADE will be applied to the Living Stroke Guidelines to ensure that their recommendations are accurate and robust.

Impairment: A problem in the structure of the body (e.g. loss of a limb) or the way the body or a body part functions (e.g. hemiplegia).

Infarction: Death of cells in an organ (e.g. the brain or heart) due to lack of blood supply.

InformMe: InformMe is the Stroke Foundation's dedicated website for health professionals working in stroke care.

Inpatient stroke care coordinator: A person who works with people with stroke and with their carers to construct care plans and discharge plans and to help coordinate the use of healthcare services during recovery in hospital.

Interdisciplinary team: group of health care professionals (including doctors, nurses, therapists, social workers, psychologists and other health personnel) working collaboratively for the common good of the patient.

Ischaemia: An inadequate flow of blood to part of the body due to blockage or constriction of the arteries that supply it.

MAGICapp: MAGICapp is an online platform for writing (authoring) and publishing guidelines and evidence summaries. MAGIC stands for MAKING GRADE the Irresistible Choice.

The platform guides authors through the different stages of planning, authoring, and publishing of information. It then publishes the guidelines online for clinicians and their patients to access. People can dig as deep into the information as they need, in order to make well-informed healthcare decisions.

MAGICapp is the technology that will be used to write and publish the Living Stroke Guidelines.

Neglect: The failure to attend or respond to or make movements towards one side of the environment.

NHMRC: The National Health and Medical Research Council (NHMRC) is the Australian Government agency that provides most of the funding for medical research. It develops health advice for the Australian community, health professionals and governments, and develops and maintains health standards. It also provides advice on ethical behaviour in health care and in conducting health and medical research.

The NHMRC are responsible for approving the stroke clinical guidelines.

Participation: Involvement in a life situation.

Participation restrictions: Problems an individual may experience in involvement in life situations.

Penumbra-based imaging: brain imaging that uses advanced MRI or CT angiography imaging to detect parts of the brain where the blood supply has been compromised but the tissue is still viable.

Percutaneous endoscopic gastrostomy (PEG): A form of enteral feeding in which nutrition is delivered via a tube that is surgically inserted into the stomach through the skin.

Pharmaceutical Benefits Scheme (PBS): A scheme whereby the costs of prescription medicine are subsidised by the Australian Government to make them more affordable.

Phonological deficits: Language deficits characterised by impaired recognition and/or selection of speech sounds.

PICO: PICO is a common way to define what research you are looking for to answer a clinical or healthcare question. Each systematic review of research is based on a specific PICO, or group of similar PICOs. PICO stands for:

P – patient, problem or population

I – intervention

C – comparison, control or comparator

O – outcome.

For example, for the question, “does care on a stroke unit improve outcomes for people with stroke?” the PICO is:

P: all people with stroke

I: care on a dedicated stroke unit (the systematic review defines what a stroke unit actually is)

C: care on a general ward

O: death, institutionalisation rate, dependency by the end of a defined follow-up period, or length of stay in a hospital or institution

Each recommendation in the Living Stroke Guidelines will be broken down into its PICO components. The scientific papers searched will need to match as closely to the PICO elements as possible.

Public consultation: Public consultation is a process by which the public's input on matters affecting them is sought. Its main goals are to improve the efficiency, transparency and public involvement, in a project – in this case in the update of the stroke guidelines.

Pulmonary embolism: Blockage of the pulmonary artery (which carries blood from the heart to the lungs) with a solid material, usually a blood clot or fat, that has travelled there via the circulatory system.

Qualitative research: Qualitative research is about words. It aims to answer questions of 'why'. It is best used to explore perspectives, attitudes and reasons.

Quantitative research: Quantitative research is about numbers. It is best used to answer questions of 'what' or 'how many'.

Randomised control trial: A controlled trial is a clinical study that compares the results of a group of people receiving a new treatment that is under investigation, against a group receiving a placebo treatment, the existing standard treatment, or no treatment at all. These comparison groups are examples of 'control' groups.

Rehabilitation: Restoration of the disabled person to optimal physical and psychological functional independence.

Research Ethics Committee: A Research Ethics Committee is a group that reviews all research proposals involving human participants to ensure that the proposals are ethically acceptable.

Research wastage:

Risk factor: A characteristic of a person (or people) that is positively associated with a particular disease or condition.

Retiring (a question): A guidelines' question is 'retired' when it is removed from the guidelines' list – this means that we will no longer search for new research (evidence) for that particular question.

Stroke unit: A section of a hospital dedicated to comprehensive acute and/or rehabilitation programs for people with a stroke.

Stroke: Sudden and unexpected damage to brain cells that causes symptoms that last for more than 24 hours in the parts of the body

controlled by those cells. Stroke happens when the blood supply to part of the brain is suddenly disrupted, either by blockage of an artery or by bleeding within the brain.

Systematic review: Systematic reviews summarise all the research that has been done on a given topic, so that health professionals, patients and policy-makers can make evidence-based decisions.

Task-specific training: Training that involves repetition of a functional task or part of the task.

Transient ischaemic attack: Stroke-like symptoms that last less than 24 hours. While TIA is not actually a stroke, it has the same cause. A TIA may be the precursor to a stroke, and people who have had a TIA require urgent assessment and intervention to prevent stroke.

Abbreviations

ACE	Angiotensin-converting enzyme
ADL	Activities of daily living
AF	Atrial fibrillation
AFO	Ankle foot orthosis
BAO	Basilar artery occlusion
BI	Barthel Index
BMI	Body mass index
BP	Blood pressure
CEA	Carotid endarterectomy
CEMRA	Contrast-enhanced magnetic resonance angiography
CI	Confidence interval
CIMT	Constraint induced movement therapy
CT	Computed tomography
CTA	Computed tomography angiography
CVD	Cardiovascular disease
DALY	Disability-adjusted life years
DBP	Diastolic blood pressure
DOAC	Direct oral anticoagulant
DSA	Digital subtraction angiography
DUS	Doppler ultrasonography
DVT	Deep vein thrombosis
DWI	Diffusion-weighted imaging
ECG	Electrocardiography
ED	Emergency department
EMG	Electromyographic feedback
EMS	Emergency medical services
ESD	Early supported discharge
ESS	European Stroke Scale
FAST	Face, Arm, Speech, Time

FEES	Fibre-optic endoscopic examination of swallowing
FeSS	Fever, Sugar, Swallowing
FFP	Fresh frozen plasma
FIM	Functional independence measure
GP	General practitioner
HR	Hazard ratio
HRQOL	Health related quality of life
HRT	Hormone replacement therapy
IA	Intra-arterial
ICH	Intracerebral haemorrhage
ICU	Intensive care unit
INR	International normalised ratio
IPC	Intermittent pneumatic compression
IV	Intravenous
LMWH	Low molecular weight heparin
LOS	Length of stay
MCA	Middle cerebral artery
MD	Mean difference
MI	Myocardial infarction
MNA	Mini Nutritional Assessment
MR	Magnetic resonance
MRA	Magnetic resonance angiography
MRI	Magnetic resonance imaging
mRS	Modified rankin scale
MST	Malnutrition screening tool
MUST	Malnutrition universal screening tool
N	Number of participants in a trial
NASCET	North American Symptomatic Carotid Endarterectomy Trial
NG	Nasogastric
NHMRC	National Health and Medical Research Council
NIHSS	National Institutes of Health Stroke Scale
NMES	Neuromuscular electrical stimulation
NNH	Numbers needed to harm
NNT	Numbers needed to treat
OR	Odds ratio

OT	Occupational therapist
PBS	Pharmaceutical Benefits Scheme
PE	Pulmonary embolism
PEG	Percutaneous endoscopic gastrostomy
PFO	Patent foramen ovale
PPV	Positive predictive value
QALYs	Quality-adjusted life years
QOL	Quality of life
RCT	Randomised controlled trial
rFVIIa	recombinant activated factor VII
RHS	Right hemisphere syndrome
ROC	Receiver operator curve
ROM	Range of motion
ROSIER	Recognition of stroke in the emergency room
RR	Relative risk
RRR	Relative risk reduction
rTMS	repetitive transcranial magnetic stimulation
rt-PA	Recombinant tissue plasminogen activator
SBP	Systolic blood pressure
SC	Subcutaneous
SD	Standard deviation
SE	Standard error
SES	Standardised effect size
SGA	Subjective global assessment
slCH	symptomatic intracerebral haemorrhage
SMD	Standardised mean difference
SSS	Scandinavian stroke scale
TEE	Transoesophageal echocardiography
TIA	Transient ischaemic attack
TOE	Transoesophageal echocardiography
TOR-BSST	Toronto Bedside Swallowing Screening test
tPA	Tissue plasminogen activator
TTE	Transthoracic echocardiography
UFH	Unfractionated heparin
UK	United Kingdom

UL	Upper limb
VF or VFS	Videofluoroscopy
VR	Virtual reality
VTE	Venous thromboembolism
WMD	Weighted mean difference

References

1. Thrift AG, Hayman N : Aboriginal and Torres Strait Islander peoples and the burden of stroke. International journal of stroke : official journal of the International Stroke Society 2007;2(1):57-9 [Pubmed Journal](#)
2. National Stroke Foundation : National Stroke Unit Program. Aboriginal Stroke Project. 2003;
3. Kilkenny MF, Harris DM, Ritchie EA, Price C, Cadilhac DA, : Hospital management and outcomes of stroke in Indigenous Australians: evidence from the 2009 Acute Care National Stroke Audit. International journal of stroke : official journal of the International Stroke Society 2013;8(3):164-71 [Pubmed Journal](#)
4. Australian Institute of Health and Welfare : Stroke and its management in Australia: an update. 2013;
5. National Vascular Disease Prevention Alliance : Guidelines for the management of absolute cardiovascular disease risk. 2012;
6. Heart Foundation : Guideline for the diagnosis and management of hypertension in adults. 2016;
7. Stroke Foundation : National Stroke Audit Acute Services. 2019; [Website](#)
8. Wardlaw JM, Brazzelli M, Chappell FM, Miranda H, Shuler K, Sandercock PAG, et al. : ABCD2 score and secondary stroke prevention. Neurology 2015;85(4):373-380 [Journal Website](#)
9. Sanders LM, Srikanth VK, Blacker DJ, Jolley DJ, Cooper KA, Phan TG : Performance of the ABCD2 score for stroke risk post TIA: meta-analysis and probability modeling. Neurology 2012;79(10):971-80 [Journal Website](#)
10. Galvin R, Geraghty C, Motterlini N, Dimitrov BD, Fahey T : Prognostic value of the ABCD(2) clinical prediction rule: a systematic review and meta-analysis. Family Practice 2011;28(4):366-376 [Journal Website](#)
11. Amarenco P, Lavallée PC, Labreuche J, Albers GW, Bornstein NM, Canhão P, et al. : One-Year Risk of Stroke after Transient Ischemic Attack or Minor Stroke. The New England journal of medicine 2016;374(16):1533-42 [Pubmed Journal](#)
12. Dai Q, Sun W, Xiong Y, Hankey GJ, Xiao L, Zhu W, et al. : From clinical to tissue-based dual TIA: Validation and refinement of ABCD3-I score. Neurology 2015;84(14):1426-32 [Journal](#)
13. Perry JJ, Sharma M., Sivilotti ML, Sutherland J., Worster A., Emond M., et al. : A prospective cohort study of patients with transient ischemic attack to identify high-risk clinical characteristics. Stroke 2014;45(1):92-100 [Journal](#)
14. Arsava EM, Furie KL, Schwamm LH, Sorensen AG, Ay H. : Prediction of early stroke risk in transient symptoms with infarction: relevance to the new tissue-based definition. Stroke 2011;42(8):2186-90 [Journal Website](#)
15. Ranta A, Dovey S, Weatherall M, O'Dea D, Gommans J, Tilyard M : Cluster randomized controlled trial of TIA electronic decision support in primary care. Neurology 2015;84(15):1545-51 [Pubmed Journal](#)
16. Lasserson DS, Mant D., Hobbs FD, Rothwell PM : Validation of a TIA recognition tool in primary and secondary care: implications for generalizability. International journal of stroke : official journal of the International Stroke Society 2015;10(5):692-6 [Journal Website](#)
17. Clarey J., Lasserson D., Levi C., Parsons M., Dewey H., Barber PA, et al. : Absolute cardiovascular risk and GP decision making in TIA and minor stroke. Fam Pract 2014;31(6):664-9 [Journal Website](#)
18. Sung VW, Johnson N., Granstaff US, Jones WJ, Meschia JF, Williams LS, et al. : Sensitivity and specificity of stroke symptom questions to detect stroke or transient ischemic attack. Neuroepidemiology 2011;36(2):100-4 [Journal](#)

19. Wardlaw J, Brazzelli M, Miranda H, Chappell F, McNamee P, Scotland G, et al. : An assessment of the cost-effectiveness of magnetic resonance, including diffusion-weighted imaging, in patients with transient ischaemic attack and minor stroke: a systematic review, meta-analysis and economic evaluation. *Health technology assessment (Winchester, England)* 2014;18(27):1-368, v-vi [Pubmed Journal](#)
20. Wasserman JK, Perry JJ, Sivilotti ML, Sutherland J., Worster A., Emond M., et al. : Computed tomography identifies patients at high risk for stroke after transient ischemic attack/nondisabling stroke: prospective, multicenter cohort study. *Stroke* 2015;46(1):114-9 [Journal](#)
21. Coutts SB, Modi J., Patel SK, Demchuk AM, Goyal M., Hill MD, et al. : CT/CT angiography and MRI findings predict recurrent stroke after transient ischemic attack and minor stroke: results of the prospective CATCH study. *Stroke* 2012;43(4):1013-7 [Journal Website](#)
22. Anticoli S, Pezzella FR, Pozzessere C, Gallelli L, Bravi MC, Caso V, et al. : Transient Ischemic Attack Fast-track and Long-Term Stroke Risk: Role of Diffusion-Weighted Magnetic Resonance Imaging. *Journal of Stroke & Cerebrovascular Diseases* 2015;24(9):2110-2116 [Journal Website](#)
23. Nah HW, Kwon SU, Kang DW, Lee DH, Kim JS : Diagnostic and prognostic value of multimodal MRI in transient ischemic attack. *International Journal of Stroke* 2014;9(7):895-901 [Journal](#)
24. Merwick A, Albers GW, Amarenco P, Arsava EM, Ay H, Calvet D, et al. : Addition of brain and carotid imaging to the ABCD² score to identify patients at early risk of stroke after transient ischaemic attack: a multicentre observational study. *The Lancet. Neurology* 2010;9(11):1060-9 [Pubmed Journal](#)
25. Lavallée PC, Meseguer E, Abboud H, Cabrejo L, Olivot J-M, Simon O, et al. : A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects. *The Lancet. Neurology* 2007;6(11):953-60 [Pubmed](#)
26. Rothwell PM, Giles MF, Chandratheva A, Marquardt L, Geraghty O, Redgrave JNE, et al. : Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. *Lancet (London, England)* 2007;370(9596):1432-42 [Pubmed](#)
27. Kamal N, Hill MD, Blacquiere DPV, Boulanger J-M, Boyle K, Buck B, et al. : Rapid Assessment and Treatment of Transient Ischemic Attacks and Minor Stroke in Canadian Emergency Departments: Time for a Paradigm Shift. *Stroke; a journal of cerebral circulation* 2015;46(10):2987-90 [Pubmed Journal](#)
28. Ranta A, Barber PA : Transient ischemic attack service provision: A review of available service models. *Neurology* 2016;86(10):947-53 [Pubmed Journal](#)
29. Sanders LM, Cadilhac DA, Srikanth VK, Chong CP, Phan TG : Is nonadmission-based care for TIA patients cost-effective?: A microcosting study. *Neurology: Clinical Practice* 2015/02/01 ;5 (1):58 -66 [Website](#)
30. Turc G, Maier B, Naggara O, Seners P, Isabel C, Tisserand M, et al. : Clinical Scales Do Not Reliably Identify Acute Ischemic Stroke Patients With Large-Artery Occlusion. *Stroke* 2016; [Pubmed Website](#)
31. Hansen CK, Christensen A, Ovesen C, Havsteen I, Christensen H : Stroke severity and incidence of acute large vessel occlusions in patients with hyper-acute cerebral ischemia: results from a prospective cohort study based on CT-angiography (CTA). *International journal of stroke : official journal of the International Stroke Society* 2015;10(3):336-42 [Pubmed Journal](#)
32. Pérez de la Ossa N, Carrera D, Gorchs M, Querol M, Millán M, Gomis M, et al. : Design and validation of a prehospital stroke scale to predict large arterial occlusion: the rapid arterial occlusion evaluation scale. *Stroke; a journal of cerebral circulation* 2014;45(1):87-91 [Pubmed Journal](#)
33. Jiang H-L, Chan CP-Y, Leung Y-K, Li Y-M, Graham CA, Rainer TH : Evaluation of the Recognition of Stroke in the Emergency Room (ROSIER) scale in Chinese patients in Hong Kong. *PloS one* 2014;9(10):e109762 [Pubmed Journal](#)
34. Whiteley WN, Wardlaw JM, Dennis MS, Sandercock PAG : Clinical scores for the identification of stroke and transient ischaemic attack in the emergency department: a cross-sectional study. *Journal of neurology, neurosurgery, and psychiatry* 2011;82(9):1006-10 [Pubmed Journal](#)

35. An S-A, Kim J, Kim O-J, Kim J-K, Kim N-K, Song J, et al. : Limited clinical value of multiple blood markers in the diagnosis of ischemic stroke. *Clinical biochemistry* 2013;46(9):710-5 [Pubmed Journal](#)
36. Whiteley W, Wardlaw J, Dennis M, Lowe G, Rumley A, Sattar N, et al. : Blood biomarkers for the diagnosis of acute cerebrovascular diseases: a prospective cohort study. *Cerebrovascular diseases (Basel, Switzerland)* 2011;32(2):141-7 [Pubmed Journal](#)
37. Vanni S, Polidori G, Pepe G, Chiarlone M, Albani A, Pagnanelli A, et al. : Use of biomarkers in triage of patients with suspected stroke. *The Journal of emergency medicine* 2011;40(5):499-505 [Pubmed Journal](#)
38. Vanacker P, Heldner MR, Amiguet M, Faouzi M, Cras P, Ntaios G, et al. : Prediction of Large Vessel Occlusions in Acute Stroke: National Institute of Health Stroke Scale Is Hard to Beat. *Critical care medicine* 2016;44(6):e336-43 [Pubmed Journal](#)
39. Meretoja A, Weir L, Ugalde M, Yassi N, Yan B, Hand P, et al. : Helsinki model cut stroke thrombolysis delays to 25 minutes in Melbourne in only 4 months. *Neurology* 2013;81(12):1071-6 [Pubmed Journal](#)
40. Meretoja A, Strbian D, Mustanoja S, Tatlisumak T, Lindsberg PJ, Kaste M : Reducing in-hospital delay to 20 minutes in stroke thrombolysis. *Neurology* 2012;79(4):306-13 [Pubmed Journal](#)
41. Brazzelli M, Sandercock PA, Chappell FM, Celani MG, Righetti E, Arestis N, et al. : Magnetic resonance imaging versus computed tomography for detection of acute vascular lesions in patients presenting with stroke symptoms. *The Cochrane database of systematic reviews* 2009;(4):CD007424 [Pubmed Journal](#)
42. Netuka D, Belšán T, Broulíková K, Mandys V, Charvát F, Malík J, et al. : Detection of carotid artery stenosis using histological specimens: a comparison of CT angiography, magnetic resonance angiography, digital subtraction angiography and Doppler ultrasonography. *Acta neurochirurgica* 2016; [Pubmed](#)
43. Chappell FM, Wardlaw JM, Young GR, Gillard JH, Roditi GH, Yip B, et al. : Carotid artery stenosis: accuracy of noninvasive tests--individual patient data meta-analysis. *Radiology* 2009;251(2):493-502 [Pubmed Journal](#)
44. Nonent M, Ben Salem D, Serfaty J-M, Buthion V, Pasco-Papon A, Rotaru C, et al. : Overestimation of moderate carotid stenosis assessed by both Doppler US and contrast enhanced 3D-MR angiography in the CARMEDAS study. *Journal of neuroradiology. Journal de neuroradiologie* 2011;38(3):148-55 [Pubmed Journal](#)
45. Tateishi Y, Tsujino A, Hamabe J, Tasaki O, Morikawa M, Horie N, et al. : Measurement of carotid stenosis using duplex ultrasonography with a microconvex array transducer: a validation with cerebral angiography. *Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association* 2013;22(8):e360-5 [Pubmed Journal](#)
46. Mair G, Boyd EV, Chappell FM, von Kummer R, Lindley RI, Sandercock P, et al. : Sensitivity and specificity of the hyperdense artery sign for arterial obstruction in acute ischemic stroke. *Stroke; a journal of cerebral circulation* 2015;46(1):102-7 [Pubmed Journal](#)
47. Zavanone C, Ragone E, Samson Y : Concordance rates of Doppler ultrasound and CT angiography in the grading of carotid artery stenosis: a systematic literature review. *Journal of neurology* 2012;259(6):1015-8 [Pubmed Journal](#)
48. Demchuk AM, Goyal M, Yeatts SD, Carrozzella J, Foster LD, Qazi E, et al. : Recanalization and clinical outcome of occlusion sites at baseline CT angiography in the Interventional Management of Stroke III trial. *Radiology* 2014;273(1):202-10 [Pubmed Journal](#)
49. Biesbroek JM, Niesten JM, Dankbaar JW, Biessels GJ, Velthuis BK, Reitsma JB, et al. : Diagnostic accuracy of CT perfusion imaging for detecting acute ischemic stroke: a systematic review and meta-analysis. *Cerebrovascular diseases (Basel, Switzerland)* 2013;35(6):493-501 [Pubmed Journal](#)
50. Lansberg MG, Lee J, Christensen S, Straka M, De Silva DA, Mlynash M, et al. : RAPID automated patient selection for reperfusion therapy: a pooled analysis of the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) and the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) Study. *Stroke; a journal of cerebral circulation* 2011;42(6):1608-14 [Pubmed Journal](#)
51. Lansberg MG, Straka M, Kemp S, Mlynash M, Wechsler LR, Jovin TG, et al. : MRI profile and response to endovascular reperfusion

after stroke (DEFUSE 2): a prospective cohort study. *The Lancet. Neurology* 2012;11(10):860-7 [Pubmed Journal](#)

52. Goyal M, Menon BK, van Zwam WH, Dippel DWJ, Mitchell PJ, Demchuk AM, et al. : Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. *Lancet (London, England)* 2016;387(10029):1723-31 [Pubmed Journal](#)

53. Earnshaw SR, McDade C, Chapman A-M, Jackson D, Schwamm L : Economic impact of using additional diagnostic tests to better select patients with stroke for intravenous thrombolysis in the United Kingdom. *Clinical therapeutics* 2012;34(7):1544-58 [Pubmed Journal](#)

54. Jackson D, Earnshaw SR, Farkouh R, Schwamm L : Cost-effectiveness of CT perfusion for selecting patients for intravenous thrombolysis: a US hospital perspective. *AJNR. American journal of neuroradiology* 2010;31(9):1669-74 [Pubmed Journal](#)

55. Young KC, Benesch CG, Jahromi BS : Cost-effectiveness of multimodal CT for evaluating acute stroke. *Neurology* 2010;75(19):1678-85 [Pubmed Journal](#)

56. Riedel CH, Zoubie J, Ulmer S, Gierthmuehlen J, Jansen O : Thin-slice reconstructions of nonenhanced CT images allow for detection of thrombus in acute stroke. *Stroke; a journal of cerebral circulation* 2012;43(9):2319-23 [Pubmed Journal](#)

57. Thomalla G, Cheng B, Ebinger M, Hao Q, Tournias T, Wu O, et al. : DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4-5 h of symptom onset (PRE-FLAIR): a multicentre observational study. *The Lancet. Neurology* 2011;10(11):978-86 [Pubmed Journal](#)

58. Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, et al. : Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. *The New England journal of medicine* 2013;368(10):893-903 [Pubmed Journal](#)

59. Buskens E, Nederkoorn PJ, Buijs-Van Der Woude T, Mali WPTM, Kappelle LJ, Eikelboom BC, et al. : Imaging of carotid arteries in symptomatic patients: cost-effectiveness of diagnostic strategies. *Radiology* 2004;233(1):101-12 [Pubmed](#)

60. Wardlaw JM, Chappell FM, Stevenson M, De Nigris E, Thomas S, Gillard J, et al. : Accurate, practical and cost-effective assessment of carotid stenosis in the UK. *Health technology assessment (Winchester, England)* 2006;10(30):iii-iv, ix-x, 1-182 [Pubmed](#)

61. Brown DL, Hoffman SN, Jacobs TL, Gruis KL, Johnson SL, Chernew ME : CT angiography is cost-effective for confirmation of internal carotid artery occlusions. *Journal of neuroimaging : official journal of the American Society of Neuroimaging* 2008;18(4):355-9 [Pubmed Journal](#)

62. Parody E, Pedraza S, García-Gil MM, Crespo C, Serena J, Dávalos A : Cost-Utility Analysis of Magnetic Resonance Imaging Management of Patients with Acute Ischemic Stroke in a Spanish Hospital. *Neurology and therapy* 2015;4(1):25-37 [Pubmed Journal](#)

63. Ang TE, Bivard A, Levi C, Ma H, Hsu CY, Campbell B, et al. : Multi-modal CT in acute stroke: wait for a serum creatinine before giving intravenous contrast? No!. *International journal of stroke : official journal of the International Stroke Society* 2015;10(7):1014-7 [Pubmed Journal](#)

64. The Royal Australian and New Zealand College of Radiologists : Iodinated Contrast Media Guideline. 2016;

65. Dussault C, Toeg H, Nathan M, Wang ZJ, Roux J-F, Secemsky E : Electrocardiographic monitoring for detecting atrial fibrillation after ischemic stroke or transient ischemic attack: systematic review and meta-analysis. *Circulation. Arrhythmia and electrophysiology* 2015;8(2):263-269 [Pubmed Journal](#)

66. Kurka N., Bobinger T., Kallmunzer B., Koehn J., Schellinger PD, Schwab S., et al. : Reliability and limitations of automated arrhythmia detection in telemetric monitoring after stroke. *Stroke* 2015;46(2):560-563 [Journal](#)

67. Afzal MR, Gunda S, Waheed S, Sehar N, Maybrook RJ, Dawn B, et al. : Role of Outpatient Cardiac Rhythm Monitoring in Cryptogenic Stroke: A Systematic Review and Meta-Analysis. *Pacing and clinical electrophysiology : PACE* 2015;38(10):1236-1245 [Pubmed Journal](#)

68. Holmes M, Rathbone J, Littlewood C, Rawdin A, Stevenson M, Stevens J, et al. : Routine echocardiography in the management of stroke and transient ischaemic attack: a systematic review and economic evaluation. Health technology assessment (Winchester, England) 2014;18(16):1-176 [Pubmed Journal](#)
69. Anzidei M, Napoli A, Zaccagna F, Di Paolo P, Saba L, Cavallo Marincola B, et al. : Diagnostic accuracy of colour Doppler ultrasonography, CT angiography and blood-pool-enhanced MR angiography in assessing carotid stenosis: a comparative study with DSA in 170 patients. La Radiologia medica 2012;117(1):54-71 [Pubmed Journal](#)
70. Tanaka K., Koga M., Sato K., Suzuki R., Minematsu K., Toyoda K. : Three-dimensional analysis of the left atrial appendage for detecting paroxysmal atrial fibrillation in acute ischemic stroke. International Journal of Stroke 2014;9(8):1045-1051 [Journal](#)
71. Kamel H., Navi BB, Elijevich L., Josephson SA, Yee AH, Fung G., et al. : Pilot randomized trial of outpatient cardiac monitoring after cryptogenic stroke. Stroke 2013;44(2):528-530 [Journal Website](#)
72. Lazzaro MA, Krishnan K, Prabhakaran S : Detection of atrial fibrillation with concurrent holter monitoring and continuous cardiac telemetry following ischemic stroke and transient ischemic attack. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2012;21(2):89-93 [Pubmed Journal](#)
73. Douen AG, Pageau N, Medic S : Serial electrocardiographic assessments significantly improve detection of atrial fibrillation 2.6-fold in patients with acute stroke. Stroke; a journal of cerebral circulation 2008;39(2):480-482 [Pubmed Journal](#)
74. Gunalp M., Atalar E., Coskun F., Yilmaz A., Aksoyek S., Aksu NM, et al. : Holter monitoring for 24 hours in patients with thromboembolic stroke and sinus rhythm diagnosed in the emergency department. Advances in Therapy 2006;23(6):854-860 [Journal](#)
75. Mayer F, Stahrenberg R, Gröschel K, Mostardt S, Biermann J, Edelmann F, et al. : Cost-effectiveness of 7-day-Holter monitoring alone or in combination with transthoracic echocardiography in patients with cerebral ischemia. Clinical research in cardiology : official journal of the German Cardiac Society 2013;102(12):875-84 [Pubmed Journal](#)
76. Tholen ATR, de Monyé C, Genders TSS, Buskens E, Dippel DWJ, van der Lugt A, et al. : Suspected carotid artery stenosis: cost-effectiveness of CT angiography in work-up of patients with recent TIA or minor ischemic stroke. Radiology 2010;256(2):585-97 [Pubmed Journal](#)
77. Meenan RT, Saha S, Chou R, Swartztrauber K, Pyle Krages K, O'Keeffe-Rosetti MC, et al. : Cost-effectiveness of echocardiography to identify intracardiac thrombus among patients with first stroke or transient ischemic attack. Medical decision making : an international journal of the Society for Medical Decision Making 2007;27(2):161-77 [Pubmed](#)
78. Groeneveld N-S, Guglielmi V, Leeflang MMG, Mattheijs Boekholdt S, Nils Planken R, Roos YBWEM, et al. : CT angiography vs echocardiography for detection of cardiac thrombi in ischemic stroke: a systematic review and meta-analysis. Journal of neurology 2020;267(6):1793-1801 [Pubmed Journal](#)
79. Mattioni A, Cenciarelli S, Eusebi P, Brazzelli M, Mazzoli T, Del Sette M, et al. : Transcranial Doppler sonography for detecting stenosis or occlusion of intracranial arteries in people with acute ischaemic stroke. The Cochrane database of systematic reviews 2020;2 CD010722 [Pubmed Journal](#)
80. Forjoe T, Asad Rahi M : Systematic review of preoperative carotid duplex ultrasound compared with computed tomography carotid angiography for carotid endarterectomy. Annals of the Royal College of Surgeons of England 2019;101(3):141-149 [Pubmed Journal](#)
81. Rojoa DM, Lodhi AQD, Kontopodis N, Ioannou CV, Labropoulos N, Antoniou GA : Ultrasonography for the diagnosis of extra-cranial carotid occlusion - diagnostic test accuracy meta-analysis. VASA. Zeitschrift fur Gefasskrankheiten 2020;49(3):195-204 [Pubmed Journal](#)
82. Campbell BCV, Majoie CBLM, Albers GW, Menon BK, Yassi N, Sharma G, et al. : Penumbra imaging and functional outcome in patients with anterior circulation ischaemic stroke treated with endovascular thrombectomy versus medical therapy: a meta-analysis of individual patient-level data. The Lancet. Neurology 2019;18(1):46-55 [Pubmed Journal](#)
83. Román LS, Menon BK, Blasco J, Hernández-Pérez M, Dávalos A, Majoie CBLM, et al. : Imaging features and safety and efficacy of endovascular stroke treatment: a meta-analysis of individual patient-level data. The Lancet. Neurology 2018;17(10):895-904 [Pubmed Journal](#)

84. Choi Y, Shin N-Y, Jang J, Ahn K-J, Kim B-S : Dual-energy CT for differentiating acute intracranial hemorrhage from contrast staining or calcification: a meta-analysis. *Neuroradiology* 2020;62(12):1617-1626 [Pubmed Journal](#)
85. Katsanos AH, Bhole R, Frogoudaki A, Giannopoulos S, Goyal N, Vrettou A-R, et al. : The value of transesophageal echocardiography for embolic strokes of undetermined source. *Neurology* 2016;87(10):988-95 [Pubmed Journal](#)
86. Kelly PJ, Albers GW, Chatzikonstantinou A, De Marchis GM, Ferrari J, George P, et al. : Validation and comparison of imaging-based scores for prediction of early stroke risk after transient ischaemic attack: a pooled analysis of individual-patient data from cohort studies. *The Lancet. Neurology* 2016;15(12):1238-1247 [Pubmed Journal](#)
87. Zhao M, Wang S, Zhang D, Zhang Y, Deng X, Zhao J : Comparison of Stroke Prediction Accuracy of ABCD2 and ABCD3-I in Patients with Transient Ischemic Attack: A Meta-Analysis. *Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association* 2017;26(10):2387-2395 [Pubmed Journal](#)
88. Perry JJ, Sivilotti MLA, Émond M, Stiell IG, Stotts G, Lee J, et al. : Prospective validation of Canadian TIA Score and comparison with ABCD2 and ABCD2i for subsequent stroke risk after transient ischaemic attack: multicentre prospective cohort study. *BMJ (Clinical research ed.)* 2021;372 n49 [Pubmed Journal](#)
89. Katsanos AH, Psaltopoulou T, Sergentanis TN, Frogoudaki A, Vrettou A-R, Ikonomidis I, et al. : Transcranial Doppler versus transthoracic echocardiography for the detection of patent foramen ovale in patients with cryptogenic cerebral ischemia: A systematic review and diagnostic test accuracy meta-analysis. *Annals of neurology* 2016;79(4):625-35 [Pubmed Journal](#)
90. Dahal K, Chapagain B, Maharjan R, Farah HW, Nazeer A, Lootens RJ, et al. : Prolonged Cardiac Monitoring to Detect Atrial Fibrillation after Cryptogenic Stroke or Transient Ischemic Attack: A Meta-Analysis of Randomized Controlled Trials. *Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc* 2016;21(4):382-8 [Pubmed Journal](#)
91. Edwards SJ, Wakefield V, Jhita T, Kew K, Cain P, Marceniuk G : Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke: a systematic review and economic evaluation. *Health technology assessment (Winchester, England)* 2020;24(5):1-184 [Pubmed Journal](#)
92. Tsigoulis G, Katsanos AH, Köhrmann M, Caso V, Perren F, Palaodimou L, et al. : Duration of Implantable Cardiac Monitoring and Detection of Atrial Fibrillation in Ischemic Stroke Patients: A Systematic Review and Meta-Analysis. *Journal of stroke* 2019;21(3):302-311 [Pubmed Journal](#)
93. Munro SF, Cooke D, Kiln-Barfoot V, Quinn T : The use and impact of 12-lead electrocardiograms in acute stroke patients: A systematic review. *European heart journal. Acute cardiovascular care* 2018;7(3):257-263 [Pubmed Journal](#)
94. Korompoki E, Del Giudice A, Hillmann S, Malzahn U, Gladstone DJ, Heuschmann P, et al. : Cardiac monitoring for detection of atrial fibrillation after TIA: A systematic review and meta-analysis. *International journal of stroke : official journal of the International Stroke Society* 2017;12(1):33-45 [Pubmed Journal](#)
95. Yan B, Tu H, Lam C, Swift C, Ho MS, Mok VCT, et al. : Nurse Led Smartphone Electrographic Monitoring for Atrial Fibrillation after Ischemic Stroke: SPOT-AF. *Journal of stroke* 2020;22(3):387-395 [Pubmed Journal](#)
96. Koh KT, Law WC, Zaw WM, Foo DHP, Tan CT, Steven A, et al. : Smartphone electrocardiogram for detecting atrial fibrillation after a cerebral ischaemic event: a multicentre randomized controlled trial. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology* 2021;23(7):1016-1023 [Pubmed Journal](#)
97. Wachter R, Gröschel K, Gelbrich G, Hamann GF, Kermer P, Liman J, et al. : Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AFRANDOMISED): an open-label randomised controlled trial. *The Lancet. Neurology* 2017;16(4):282-290 [Pubmed Journal](#)
98. Ross LS, Bettin M, Kochhäuser S, Ritter M, Minnerup J, Eckardt L, et al. : Sensitive Detection of Atrial Fibrillation in Acute Stroke Patients by Short-Term Bedside Electrocardiography Monitoring Software Analysis. *Cerebrovascular diseases (Basel, Switzerland)* 2018;45(1-2):54-60 [Pubmed Journal](#)

99. Kaura A, Sztriha L, Chan FK, Aeron-Thomas J, Gall N, Piechowski-Jozwiak B, et al. : Early prolonged ambulatory cardiac monitoring in stroke (EPACS): an open-label randomised controlled trial. *European journal of medical research* 2019;24(1):25 [Pubmed Journal](#)
100. Gomis M, Dávalos A, Purroy F, Cardona P, Rodríguez-Campello A, Martí-Fàbregas J, et al. : Stroke Risk Analysis, a System With a High Detection Rate of Atrial Fibrillation in Stroke and Transient Ischemic Attack. *Stroke* 2020;51(1):262-267 [Pubmed Journal](#)
101. Magnusson P, Lyren A, Mattsson G : Diagnostic yield of chest and thumb ECG after cryptogenic stroke, Transient ECG Assessment in Stroke Evaluation (TEASE): an observational trial. *BMJ open* 2020;10(9):e037573 [Pubmed Journal](#)
102. Kułach A, Dewerenda M, Majewski M, Lasek-Bal A, Gąsior Z : 72 hour Holter monitoring, 7 day Holter monitoring, and 30 day intermittent patient-activated heart rhythm recording in detecting arrhythmias in cryptogenic stroke patients free from arrhythmia in a screening 24 h Holter. *Open medicine (Warsaw, Poland)* 2020;15(1):697-701 [Pubmed Journal](#)
103. Han F, Zuo C, Zheng G : A systematic review and meta-analysis to evaluate the diagnostic accuracy of recognition of stroke in the emergency department (ROSIER) scale. *BMC neurology* 2020;20(1):304 [Pubmed Journal](#)
104. Rudd M, Buck D, Ford GA, Price CI : A systematic review of stroke recognition instruments in hospital and prehospital settings. *Emergency medicine journal : EMJ* 2016;33(11):818-822 [Pubmed Journal](#)
105. Zhelev Z, Walker G, Henschke N, Fridhandler J, Yip S : Prehospital stroke scales as screening tools for early identification of stroke and transient ischemic attack. *The Cochrane database of systematic reviews* 2019;4 CD011427 [Pubmed Journal](#)
106. De Luca A, Mariani M, Riccardi MT, Damiani G : The role of the Cincinnati Prehospital Stroke Scale in the emergency department: evidence from a systematic review and meta-analysis. *Open access emergency medicine : OAEM* 2019;11 147-159 [Pubmed Journal](#)
107. Katyal A, Calic Z, Killingsworth M, Bhaskar SMM : Diagnostic and prognostic utility of computed tomography perfusion imaging in posterior circulation acute ischemic stroke: A systematic review and meta-analysis. *European journal of neurology* 2021;28(8):2657-2668 [Pubmed Journal](#)
108. Huang W-Y, Lee M, Sung S-F, Tang S-C, Chang K-H, Huang Y-S, et al. : Atrial fibrillation trial to evaluate real-world procedures for their utility in helping to lower stroke events: A randomized clinical trial. *International journal of stroke : official journal of the International Stroke Society* 2021;16(3):300-310 [Pubmed Journal](#)
109. Haeusler KG, Kirchhof P, Kunze C, Tütüncü S, Fiessler C, Malsch C, et al. : Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multicentre study. *The Lancet. Neurology* 2021;20(6):426-436 [Pubmed Journal](#)
110. Ko D, Dai Q, Flynn DB, Bosch NA, Helm RH, Monahan KM, et al. : Meta-Analysis of Randomized Clinical Trials Comparing the Impact of Implantable Loop Recorder Versus Usual Care After Ischemic Stroke for Detection of Atrial Fibrillation and Stroke Risk. *The American journal of cardiology* 2022;162 100-104 [Pubmed Journal](#)
111. Tan X, Wang Z, Wu X, Zhang J, Song Z, Qiu Y, et al. : The efficacy and safety of insertable cardiac monitor on atrial fibrillation detection in patients with ischemic stroke: a systematic review and meta-analysis. *Journal of neurology* 2022;269(5):2338-2345 [Pubmed Journal](#)
112. Chen X, Zhao X, Xu F, Guo M, Yang Y, Zhong L, et al. : A Systematic Review and Meta-Analysis Comparing FAST and BEFAST in Acute Stroke Patients. *Frontiers in neurology* 2021;12 765069 [Pubmed Journal](#)
113. Galecio-Castillo M, Vivanco-Suarez J, Zevallos CB, Dajles A, Weng J, Farooqui M, et al. : Direct to angiosuite strategy versus standard workflow triage for endovascular therapy: systematic review and meta-analysis. *Journal of neurointerventional surgery* [Pubmed Journal](#)
114. Cassola N, Baptista-Silva JC, Nakano LC, Flumignan CD, Sesso R, Vasconcelos V, et al. : Duplex ultrasound for diagnosing symptomatic carotid stenosis in the extracranial segments. *The Cochrane database of systematic reviews* 7(7):CD013172 [Pubmed Journal](#)